Wiesje M Van Der Flier

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1804743/publications.pdf

Version: 2024-02-01

846 papers	46,559 citations	1701 104 h-index	3725 179 g-index
970 all docs	970 docs citations	970 times ranked	32872 citing authors

#	Article	IF	Citations
1	A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease. Alzheimer's and Dementia, 2014, 10, 844-852.	0.4	1,863
2	Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimerâ€™s disease risk. Nature Genetics, 2019, 51, 404-413.	9.4	1,625
3	Alzheimer's disease. Lancet, The, 2021, 397, 1577-1590.	6.3	1,530
4	Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia. JAMA - Journal of the American Medical Association, 2015, 313, 1924.	3.8	1,166
5	CSF Biomarkers and Incipient Alzheimer Disease in Patients With Mild Cognitive Impairment. JAMA - Journal of the American Medical Association, 2009, 302, 385.	3.8	1,009
6	New insights into the genetic etiology of Alzheimerâ€™s disease and related dementias. Nature Genetics, 2022, 54, 412-436.	9.4	700
7	The characterisation of subjective cognitive decline. Lancet Neurology, The, 2020, 19, 271-278.	4.9	627
8	Heterogeneity of small vessel disease: a systematic review of MRI and histopathology correlations. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 126-135.	0.9	588
9	Prevalence of Amyloid PET Positivity in Dementia Syndromes. JAMA - Journal of the American Medical Association, 2015, 313, 1939.	3.8	501
10	The effect of physical activity on cognitive function in patients with dementia: A meta-analysis of randomized control trials. Ageing Research Reviews, 2016, 25, 13-23.	5.0	455
11	Consensus classification of posterior cortical atrophy. Alzheimer's and Dementia, 2017, 13, 870-884.	0.4	423
12	The behavioural/dysexecutive variant of Alzheimerâ€™s disease: clinical, neuroimaging and pathological features. Brain, 2015, 138, 2732-2749.	3.7	397
13	Implementation of subjective cognitive decline criteria in research studies. Alzheimer's and Dementia, 2017, 13, 296-311.	0.4	375
14	Epidemiology and risk factors of dementia. Journal of Neurology, Neurosurgery and Psychiatry, 2005, 76, v2-v7.	0.9	374
15	Blood-based biomarkers for Alzheimer's disease: towards clinical implementation. Lancet Neurology, The, 2022, 21, 66-77.	4.9	360
16	Early-Versus Late-Onset Alzheimer's Disease: More than Age Alone. Journal of Alzheimer's Disease, 2010, 19, 1401-1408.	1.2	359
17	Vascular cognitive impairment. Nature Reviews Disease Primers, 2018, 4, 18003.	18.1	358
18	Alzheimer's disease: connecting findings from graph theoretical studies of brain networks. Neurobiology of Aging, 2013, 34, 2023-2036.	1.5	355

#	Article	IF	Citations
19	Progression of White Matter Hyperintensities and Incidence of New Lacunes Over a 3-Year Period. Stroke, 2008, 39, 1414-1420.	1.0	348
20	Resting-state fMRI changes in Alzheimer's disease and mild cognitive impairment. Neurobiology of Aging, 2012, 33, 2018-2028.	1.5	337
21	Functional neural network analysis in frontotemporal dementia and Alzheimer's disease using EEG and graph theory. BMC Neuroscience, 2009, 10, 101.	0.8	317
22	Subjective Cognitive Decline in Older Adults: An Overview of Self-Report Measures Used Across 19 International Research Studies. Journal of Alzheimer's Disease, 2015, 48, S63-S86.	1.2	317
23	Hippocampal atrophy rates in Alzheimer disease. Neurology, 2009, 72, 999-1007.	1.5	315
24	Small Vessel Disease and General Cognitive Function in Nondisabled Elderly. Stroke, 2005, 36, 2116-2120.	1.0	311
25	Optimizing Patient Care and Research: The Amsterdam Dementia Cohort. Journal of Alzheimer's Disease, 2014, 41, 313-327.	1.2	307
26	Amyloid-Î²(1â€“42), Total Tau, and Phosphorylated Tau as Cerebrospinal Fluid Biomarkers for the Diagnosis of Alzheimer Disease. Clinical Chemistry, 2010, 56, 248-253.	1.5	301
27	Visual assessment of posterior atrophy development of a MRI rating scale. European Radiology, 2011, 21, 2618-2625.	2.3	299
28	Brain microbleeds and Alzheimerâ€™s disease: innocent observation or key player?. Brain, 2011, 134, 335-344.	3.7	291
29	Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and APOE genotype. Alzheimer's and Dementia, 2019, 15, 888-898.	0.4	290
30	Prevalence and prognosis of Alzheimerâ€™s disease at the mild cognitive impairment stage. Brain, 2015, 138, 1327-1338.	3.7	284
31	Early-onset versus late-onset Alzheimer's disease: the case of the missing APOE É›4 allele. Lancet Neurology, The, 2011, 10, 280-288.	4.9	273
32	Prevalence and severity of microbleeds in a memory clinic setting. Neurology, 2006, 66, 1356-1360.	1.5	270
33	Standardized evaluation of algorithms for computer-aided diagnosis of dementia based on structural MRI: The CADDementia challenge. NeuroImage, 2015, 111, 562-579.	2.1	266
34	Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort. Neurology, 2012, 78, 47-54.	1.5	255
35	Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease. Alzheimer's and Dementia, 2015, 11, 1180-1190.	0.4	254
36	Bloodâ€“brain barrier P-glycoprotein function in Alzheimer's disease. Brain, 2012, 135, 181-189.	3.7	252

#	Article	IF	Citations
37	Precuneus atrophy in early-onset Alzheimerâ€™s disease: a morphometric structural MRI study. Neuroradiology, 2007, 49, 967-976.	1.1	251
38	The cerebrospinal fluid â€œAlzheimer profileâ€: Easily said, but what does it mean?. Alzheimer's and Dementia, 2014, 10, 713.	0.4	249
39	Heterogeneity of white matter hyperintensities in Alzheimer's disease: post-mortem quantitative MRI and neuropathology. Brain, 2008, 131, 3286-3298.	3.7	246
40	Subjective cognitive decline and rates of incident Alzheimer's disease and nonâ€“Alzheimer's disease dementia. Alzheimer's and Dementia, 2019, 15, 465-476.	0.4	232
41	Suspected non-Alzheimer disease pathophysiology â€” concept and controversy. Nature Reviews Neurology, 2016, 12, 117-124.	4.9	230
42	Plasma Amyloid as Prescreener for the Earliest <scp>A</scp>lzheimer Pathological Changes. Annals of Neurology, 2018, 84, 648-658.	2.8	230
43	Amsterdam Dementia Cohort: Performing Research to Optimize Care. Journal of Alzheimer's Disease, 2018, 62, 1091-1111.	1.2	228
44	A meta-analysis of genome-wide association studies identifies multiple longevity genes. Nature Communications, 2019, 10, 3669.	5.8	214
45	Cerebral Blood Flow Measured with 3D Pseudocontinuous Arterial Spin-labeling MR Imaging in Alzheimer Disease and Mild Cognitive Impairment: A Marker for Disease Severity. Radiology, 2013, 267, 221-230.	3.6	206
46	Patients With Alzheimer Disease With Multiple Microbleeds. Stroke, 2009, 40, 3455-3460.	1.0	202
47	Consensus guidelines for lumbar puncture in patients with neurological diseases. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 8, 111-126.	1.2	197
48	Atrophy patterns in early clinical stages across distinct phenotypes of <scp>A</scp>lzheimer's disease. Human Brain Mapping, 2015, 36, 4421-4437.	1.9	196
49	Disrupted modular brain dynamics reflect cognitive dysfunction in Alzheimer's disease. NeuroImage, 2012, 59, 3085-3093.	2.1	190
50	Incident lacunes influence cognitive decline. Neurology, 2011, 76, 1872-1878.	1.5	183
51	Neurogranin as a Cerebrospinal Fluid Biomarker for Synaptic Loss in Symptomatic Alzheimer Disease. JAMA Neurology, 2015, 72, 1275.	4.5	183
52	Performance and complications of lumbar puncture in memory clinics: Results of the multicenter lumbar puncture feasibility study. Alzheimer's and Dementia, 2016, 12, 154-163.	0.4	179
53	Genetic analysis implicates APOE, SNCA and suggests lysosomal dysfunction in the etiology of dementia with Lewy bodies. Human Molecular Genetics, 2014, 23, 6139-6146.	1.4	178
54	Longitudinal Cognitive Decline in Subcortical Ischemic Vascular Disease â€“ The LADIS Study. Cerebrovascular Diseases, 2009, 27, 384-391.	0.8	167

#	Article	IF	Citations
55	Hippocampal atrophy on MRI in frontotemporal lobar degeneration and Alzheimer's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2006, 77, 439-442.	0.9	165
56	Standardized Assessment of Automatic Segmentation of White Matter Hyperintensities and Results of the WMH Segmentation Challenge. IEEE Transactions on Medical Imaging, 2019, 38, 2556-2568.	5.4	165
57	Cerebrospinal fluid AÎ²42 is the best predictor of clinical progression in patients with subjective complaints. Alzheimer's and Dementia, 2013, 9, 481-487.	0.4	164
58	Relationship of Cerebrospinal Fluid Markers to¹¹C-PiB and¹⁸F-FDDNP Binding. Journal of Nuclear Medicine, 2009, 50, 1464-1470.	2.8	162
59	Prediction of dementia in MCI patients based on core diagnostic markers for Alzheimer disease. Neurology, 2013, 80, 1048-1056.	1.5	161
60	CSF biomarkers and medial temporal lobe atrophy predict dementia in mild cognitive impairment. Neurobiology of Aging, 2007, 28, 1070-1074.	1.5	160
61	Profile of Cognitive Impairment in Chronic Heart Failure. Journal of the American Geriatrics Society, 2007, 55, 1764-1770.	1.3	160
62	Impact of molecular imaging on the diagnostic process in a memory clinic. Alzheimer's and Dementia, 2013, 9, 414-421.	0.4	159
63	A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease. Annals of Clinical Biochemistry, 2009, 46, 235-240.	0.8	157
64	Memory complaints in patients with normal cognition are associated with smaller hippocampal volumes. Journal of Neurology, 2004, 251, 671-5.	1.8	156
65	Early Onset Alzheimer's Disease is Associated with a Distinct Neuropsychological Profile. Journal of Alzheimer's Disease, 2012, 30, 101-108.	1.2	156
66	Different patterns of gray matter atrophy in early- and late-onset Alzheimerâ€™s disease. Neurobiology of Aging, 2013, 34, 2014-2022.	1.5	156
67	Age and diagnostic performance of Alzheimer disease CSF biomarkers. Neurology, 2012, 78, 468-476.	1.5	154
68	Global estimates on the number of persons across the Alzheimer's disease continuum. Alzheimer's and Dementia, 2023, 19, 658-670.	0.4	146
69	Longitudinal imaging of Alzheimer pathology using [11C]PIB, [18F]FDDNP and [18F]FDG PET. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 990-1000.	3.3	145
70	Microglial activation in Alzheimer's disease: an (R)-[11C]PK11195 positron emission tomography study. Neurobiology of Aging, 2013, 34, 128-136.	1.5	145
71	Integrative EEG biomarkers predict progression to Alzheimer's disease at the MCI stage. Frontiers in Aging Neuroscience, 2013, 5, 58.	1.7	143
72	Circulating metabolites and general cognitive ability and dementia: Evidence from 11 cohort studies. Alzheimer's and Dementia, 2018, 14, 707-722.	0.4	143

#	Article	IF	Citations
73	White Matter Hyperintensities Rather Than Lacunar Infarcts Are Associated With Depressive Symptoms in Older People: The LADIS Study. American Journal of Geriatric Psychiatry, 2006, 14, 834-841.	0.6	141
74	Tau and p-tau as CSF biomarkers in dementia: a meta-analysis. Clinical Chemistry and Laboratory Medicine, 2011, 49, 353-366.	1.4	140
75	Associations Between Cerebral Small-Vessel Disease and Alzheimer Disease Pathology as Measured by Cerebrospinal Fluid Biomarkers. JAMA Neurology, 2014, 71, 855.	4.5	140
76	Common variants in Alzheimerâ€™s disease and risk stratification by polygenic risk scores. Nature Communications, 2021, 12, 3417.	5.8	140
77	Differential diagnosis of neurodegenerative diseases using structural MRI data. NeuroImage: Clinical, 2016, 11, 435-449.	1.4	137
78	Whole-Brain Atrophy Rate and Cognitive Decline: Longitudinal MR Study of Memory Clinic Patients. Radiology, 2008, 248, 590-598.	3.6	133
79	Declining functional connectivity and changing hub locations in Alzheimerâ€™s disease: an EEG study. BMC Neurology, 2015, 15, 145.	0.8	133
80	Association of Cerebral Amyloid-Î² Aggregation With Cognitive Functioning in Persons Without Dementia. JAMA Psychiatry, 2018, 75, 84.	6.0	133
81	Selective impairment of hippocampus and posterior hub areas in Alzheimerâ€™s disease: an MEG-based multiplex network study. Brain, 2017, 140, 1466-1485.	3.7	132
82	Prevalence of amyloidâ€Î² pathology in distinct variants of primary progressive aphasia. Annals of Neurology, 2018, 84, 729-740.	2.8	132
83	Brain magnetic resonance imaging abnormalities in patients with heart failure. European Journal of Heart Failure, 2007, 9, 1003-1009.	2.9	130
84	CSF biomarkers predict rate of cognitive decline in Alzheimer disease. Neurology, 2009, 73, 1353-1358.	1.5	130
85	Injury markers predict time to dementia in subjects with MCI and amyloid pathology. Neurology, 2012, 79, 1809-1816.	1.5	129
86	Combination of plasma amyloid beta(1-42/1-40) and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology. Alzheimer's Research and Therapy, 2020, 12, 118.	3.0	129
87	Progression of Mild Cognitive Impairment to Dementia. Stroke, 2009, 40, 1269-1274.	1.0	128
88	Magnetization transfer imaging in normal aging, mild cognitive impairment, and Alzheimer's disease. Annals of Neurology, 2002, 52, 62-67.	2.8	127
89	Hippocampal atrophy in Alzheimer disease: Age matters. Neurology, 2006, 66, 236-238.	1.5	127
90	Unbiased Approach to Counteract Upward Drift in Cerebrospinal Fluid Amyloid-Î² 1â€“42 Analysis Results. Clinical Chemistry, 2018, 64, 576-585.	1.5	126

#	Article	IF	Citations
91	Microglial activation in healthy aging. Neurobiology of Aging, 2012, 33, 1067-1072.	1.5	125
92	Brain atrophy accelerates cognitive decline in cerebral small vessel disease. Neurology, 2012, 78, 1785-1792.	1.5	125
93	Efficacy, safety and tolerability of rivastigmine capsules in patients with probable vascular dementia: the VantagE study. Current Medical Research and Opinion, 2008, 24, 2561-2574.	0.9	124
94	Clinical Relevance of Improved Microbleed Detection by Susceptibility-Weighted Magnetic Resonance Imaging. Stroke, 2011, 42, 1894-1900.	1.0	124
95	Global Prevalence of Young-Onset Dementia. JAMA Neurology, 2021, 78, 1080.	4.5	124
96	Preclinical AD predicts decline in memory and executive functions in subjective complaints. Neurology, 2013, 81, 1409-1416.	1.5	122
97	Mild cognitive impairment with suspected nonamyloid pathology (SNAP). Neurology, 2015, 84, 508-515.	1.5	122
98	Diagnostic Imaging of Patients in a Memory Clinic: Comparison of MR Imaging and 64â€“Detector Row CT. Radiology, 2009, 253, 174-183.	3.6	121
99	CSF biomarker levels in early and late onset Alzheimer's disease. Neurobiology of Aging, 2009, 30, 1895-1901.	1.5	121
100	Detection of Alzheimer Pathology In Vivo Using Both ¹¹C-PIB and ¹⁸F-FDDNP PET. Journal of Nuclear Medicine, 2009, 50, 191-197.	2.8	119
101	MRI Biomarkers of Vascular Damage and Atrophy Predicting Mortality in a Memory Clinic Population. Stroke, 2009, 40, 492-498.	1.0	118
102	Incidence of cerebral microbleeds. Neurology, 2010, 74, 1954-1960.	1.5	115
103	Longitudinal changes of CSF biomarkers in memory clinic patients. Neurology, 2007, 69, 1006-1011.	1.5	114
104	Prediction of Alzheimer disease in subjects with amnestic and nonamnestic MCI. Neurology, 2013, 80, 1124-1132.	1.5	110
105	Simple versus complex assessment of white matter hyperintensities in relation to physical performance and cognition: the LADIS study. Journal of Neurology, 2006, 253, 1189-1196.	1.8	109
106	Amyloid burden and metabolic function in early-onset Alzheimer's disease: parietal lobe involvement. Brain, 2012, 135, 2115-2125.	3.7	109
107	Concordance Between Cerebrospinal Fluid Biomarkers and [11C]PIB PET in a Memory Clinic Cohort. Journal of Alzheimer's Disease, 2014, 41, 801-807.	1.2	109
108	Alzheimerâ€™s disease cerebrospinal fluid biomarker in cognitively normal subjects. Brain, 2015, 138, 2701-2715.	3.7	109

#	Article	IF	Citations
109	Brain network alterations in Alzheimer's disease measured by Eigenvector centrality in fMRI are related to cognition and CSF biomarkers. Human Brain Mapping, 2014, 35, 2383-2393.	1.9	108
110	The Contribution of Medial Temporal Lobe Atrophy and Vascular Pathology to Cognitive Impairment in Vascular Dementia. Stroke, 2007, 38, 3182-3185.	1.0	107
111	Single-Subject Grey Matter Graphs in Alzheimer's Disease. PLoS ONE, 2013, 8, e58921.	1.1	107
112	CSF and MRI markers independently contribute to the diagnosis of Alzheimer's disease. Neurobiology of Aging, 2008, 29, 669-675.	1.5	103
113	Behavioural and psychological symptoms in vascular dementia; differences between small- and large-vessel disease. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, 547-551.	0.9	103
114	Differential effects of cognitive reserve and brain reserve on cognition in Alzheimer disease. Neurology, 2018, 90, e149-e156.	1.5	103
115	Location of lacunar infarcts correlates with cognition in a sample of non-disabled subjects with age-related white-matter changes: the LADIS study. Journal of Neurology, Neurosurgery and Psychiatry, 2009, 80, 478-483.	0.9	102
116	Genome-wide significant risk factors for Alzheimerâ€™s disease: role in progression to dementia due to Alzheimer's disease among subjects with mild cognitive impairment. Molecular Psychiatry, 2017, 22, 153-160.	4.1	102
117	Characterization of pathogenic SORL1 genetic variants for association with Alzheimerâ€™s disease: a clinical interpretation strategy. European Journal of Human Genetics, 2017, 25, 973-981.	1.4	102
118	Atrophy subtypes in prodromal Alzheimerâ€™s disease are associated with cognitive decline. Brain, 2018, 141, 3443-3456.	3.7	102
119	Association of Amyloid Positron Emission Tomography With Changes in Diagnosis and Patient Treatment in an Unselected Memory Clinic Cohort. JAMA Neurology, 2018, 75, 1062.	4.5	102
120	Most rapid cognitive decline in APOE Îµ4 negative Alzheimer's disease with early onset. Psychological Medicine, 2009, 39, 1907-1911.	2.7	101
121	Cerebrospinal fluid VILIP-1 and YKL-40, candidate biomarkers to diagnose, predict and monitor Alzheimerâ€™s disease in a memory clinic cohort. Alzheimer's Research and Therapy, 2015, 7, 59.	3.0	101
122	Concomitant AD pathology affects clinical manifestation and survival in dementia with Lewy bodies. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 113-118.	0.9	100
123	Differential effect of APOE genotype on amyloid load and glucose metabolism in AD dementia. Neurology, 2013, 80, 359-365.	1.5	99
124	Cerebral perfusion in the predementia stages of Alzheimerâ€™s disease. European Radiology, 2016, 26, 506-514.	2.3	99
125	Lower cerebral blood flow is associated with impairment in multiple cognitive domains in Alzheimer's disease. Alzheimer's and Dementia, 2017, 13, 531-540.	0.4	99
126	Diagnostic impact of [18F]flutemetamol PET in early-onset dementia. Alzheimer's Research and Therapy, 2017, 9, 2.	3.0	98

#	Article	IF	Citations
127	Non-Pharmacologic Interventions for Older Adults with Subjective Cognitive Decline: Systematic Review, Meta-Analysis, and Preliminary Recommendations. Neuropsychology Review, 2017, 27, 245-257.	2.5	97
128	Lower cerebral blood flow is associated with faster cognitive decline in Alzheimerâ€™s disease. European Radiology, 2017, 27, 1169-1175.	2.3	97
129	ATN classification and clinical progression in subjective cognitive decline. Neurology, 2020, 95, e46-e58.	1.5	97
130	Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. JAMA Neurology, 2022, 79, 228.	4.5	97
131	Medial temporal lobe atrophy and white matter hyperintensities are associated with mild cognitive deficits in non-disabled elderly people: the LADIS study. Journal of Neurology, Neurosurgery and Psychiatry, 2005, 76, 1497-1500.	0.9	96
132	CSF biomarkers in relationship to cognitive profiles in Alzheimer disease. Neurology, 2009, 72, 1056-1061.	1.5	96
133	Whole-brain atrophy rate in Alzheimer disease. Neurology, 2008, 70, 1836-1841.	1.5	94
134	Clinical value of neurofilament and phospho-tau/tau ratio in the frontotemporal dementia spectrum. Neurology, 2018, 90, e1231-e1239.	1.5	94
135	Synaptic proteins in CSF as potential novel biomarkers for prognosis in prodromal Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2018, 10, 5.	3.0	94
136	Alzheimer's disease first symptoms are age dependent: Evidence fromÂthe NACC dataset. Alzheimer's and Dementia, 2015, 11, 1349-1357.	0.4	93
137	Genetic risk factors for the posterior cortical atrophy variant of Alzheimer's disease. Alzheimer's and Dementia, 2016, 12, 862-871.	0.4	93
138	Dementia with Lewy bodies and AD are not associated with occipital lobe atrophy on MRI. Neurology, 2001, 57, 2117-2120.	1.5	91
139	Neuroimaging and Correlates of Cognitive Function among Patients with Heart Failure. Dementia and Geriatric Cognitive Disorders, 2007, 24, 418-423.	0.7	91
140	Global dynamical analysis of the EEG in Alzheimerâ€™s disease: Frequency-specific changes of functional interactions. Clinical Neurophysiology, 2008, 119, 837-841.	0.7	91
141	EEG spectral analysis as a putative early prognostic biomarker in nondemented, amyloid positive subjects. Neurobiology of Aging, 2017, 57, 133-142.	1.5	91
142	Whole-brain atrophy rate and CSF biomarker levels in MCI and AD: A longitudinal study. Neurobiology of Aging, 2010, 31, 758-764.	1.5	90
143	The identification of cognitive subtypes in Alzheimer's disease dementia using latent class analysis. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 235-243.	0.9	89
144	Diabetes mellitus, hypertension and medial temporal lobe atrophy: the LADIS study. Diabetic Medicine, 2007, 24, 166-171.	1.2	88

#	Article	IF	Citations
145	Accelerating regional atrophy rates in the progression from normal aging to Alzheimerâ€™s disease. European Radiology, 2009, 19, 2826-2833.	2.3	88
146	White Matter Lesion Progression in LADIS. Stroke, 2012, 43, 2643-2647.	1.0	88
147	Relation between subcortical grey matter atrophy and conversion from mild cognitive impairment to Alzheimer's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 425-432.	0.9	88
148	CSF Î±-Synuclein Does Not Discriminate Dementia with Lewy Bodies from Alzheimer's Disease. Journal of Alzheimer's Disease, 2010, 22, 87-95.	1.2	87
149	Subjective Cognitive Impairment Cohort (SCIENCe): study design and first results. Alzheimer's Research and Therapy, 2018, 10, 76.	3.0	87
150	A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimerâ€™s disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity. Acta Neuropathologica, 2019, 138, 237-250.	3.9	87
151	Clinical and analytical comparison of six Simoa assays for plasma P-tau isoforms P-tau181, P-tau217, and P-tau231. Alzheimer's Research and Therapy, 2021, 13, 198.	3.0	87
152	The effect of APOE genotype on clinical phenotype in Alzheimer disease. Neurology, 2006, 67, 526-527.	1.5	85
153	Disruption of Functional Brain Networks in Alzheimer's Disease: What Can We Learn from Graph Spectral Analysis of Resting-State Magnetoencephalography?. Brain Connectivity, 2012, 2, 45-55.	0.8	85
154	Relationship between progression of brain white matter changes and late-life depression: 3-year results from the LADIS study. British Journal of Psychiatry, 2012, 201, 40-45.	1.7	85
155	Trajectories of cognitive decline in different types of dementia. Psychological Medicine, 2015, 45, 1051-1059.	2.7	85
156	Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study. Lancet Neurology, The, 2019, 18, 1034-1044.	4.9	85
157	Serum markers glial fibrillary acidic protein and neurofilament light for prognosis and monitoring in cognitively normal older people: a prospective memory clinic-based cohort study. The Lancet Healthy Longevity, 2021, 2, e87-e95.	2.0	85
158	The blood brain barrier in Alzheimerâ€™s disease. Vascular Pharmacology, 2017, 89, 12-18.	1.0	84
159	Early-Onset Dementia Is Associated with Higher Mortality. Dementia and Geriatric Cognitive Disorders, 2008, 26, 147-152.	0.7	82
160	Diffusion-Weighted Imaging and Cognition in the Leukoariosis and Disability in the Elderly Study. Stroke, 2010, 41, e402-8.	1.0	82
161	Discriminative and prognostic potential of cerebrospinal fluid phosphoTau/tau ratio and neurofilaments for frontotemporal dementia subtypes. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2015, 1, 505-512.	1.2	81
162	Neurological Signs in Relation to Type of Cerebrovascular Disease in Vascular Dementia. Stroke, 2008, 39, 317-322.	1.0	80

#	Article	IF	Citations
163	Cerebral perfusion and glucose metabolism in Alzheimerâ€™s disease and frontotemporal dementia: two sides of the same coin?. European Radiology, 2015, 25, 3050-3059.	2.3	80
164	Reliability and Sensitivity of Visual Scales versus Volumetry for Evaluating White Matter Hyperintensity Progression. Cerebrovascular Diseases, 2008, 25, 247-253.	0.8	79
165	Alzheimer Disease and Behavioral Variant Frontotemporal Dementia: Automatic Classification Based on Cortical Atrophy for Single-Subject Diagnosis. Radiology, 2016, 279, 838-848.	3.6	79
166	Î±â€Synuclein species as potential cerebrospinal fluid biomarkers for dementia with lewy bodies. Movement Disorders, 2018, 33, 1724-1733.	2.2	79
167	Genome-wide analysis of genetic correlation in dementia with Lewy bodies, Parkinson's and Alzheimer's diseases. Neurobiology of Aging, 2016, 38, 214.e7-214.e10.	1.5	78
168	Baseline predictors of rates of hippocampal atrophy in mild cognitive impairment. Neurology, 2007, 69, 1491-1497.	1.5	77
169	Cerebrospinal Fluid Alzheimerâ€™s Disease Biomarkers Across the Spectrum of Lewy Body Diseases: Results from a Large Multicenter Cohort. Journal of Alzheimer's Disease, 2016, 54, 287-295.	1.2	77
170	Interpreting Biomarker Results in Individual Patients With Mild Cognitive Impairment in the Alzheimerâ€™s Biomarkers in Daily Practice (ABIDE) Project. JAMA Neurology, 2017, 74, 1481.	4.5	77
171	On the Etiology of Incident Brain Lacunes. Stroke, 2008, 39, 3083-3085.	1.0	76
172	Alzheimerâ€™s disease: The state of the art in resting-state magnetoencephalography. Clinical Neurophysiology, 2017, 128, 1426-1437.	0.7	76
173	A clinical-radiological framework of the right temporal variant of frontotemporal dementia. Brain, 2020, 143, 2831-2843.	3.7	76
174	Interaction of medial temporal lobe atrophy and white matter hyperintensities in AD. Neurology, 2004, 62, 1862-1864.	1.5	75
175	BACE1 Activity in Cerebrospinal Fluid and Its Relation to Markers of AD Pathology. Journal of Alzheimer's Disease, 2010, 20, 253-260.	1.2	75
176	Test sequence of CSF and MRI biomarkers for prediction of AD in subjects with MCI. Neurobiology of Aging, 2012, 33, 2272-2281.	1.5	75
177	Slowing of Hippocampal Activity Correlates with Cognitive Decline in Early Onset Alzheimerâ€™s Disease. An MEG Study with Virtual Electrodes. Frontiers in Human Neuroscience, 2016, 10, 238.	1.0	75
178	Injury Markers but not Amyloid Markers are Associated with Rapid Progression from Mild Cognitive Impairment to Dementia in Alzheimer's Disease. Journal of Alzheimer's Disease, 2012, 29, 319-327.	1.2	73
179	White Matter Hyperintensities Relate to Clinical Progression in Subjective Cognitive Decline. Stroke, 2015, 46, 2661-2664.	1.0	73
180	The use of EEG in the diagnosis of dementia with Lewy bodies. Journal of Neurology, Neurosurgery and Psychiatry, 2008, 79, 377-380.	0.9	72

#	Article	IF	Citations
181	Cerebral Blood Flow by Using Pulsed Arterial Spin-Labeling in Elderly Subjects with White Matter Hyperintensities. American Journal of Neuroradiology, 2008, 29, 1296-1301.	1.2	72
182	Microbleeds do not affect rate of cognitive decline in Alzheimer disease. Neurology, 2012, 79, 763-769.	1.5	72
183	Increased Number of Microinfarcts in Alzheimer Disease at 7-T MR Imaging. Radiology, 2014, 270, 205-211.	3.6	72
184	Prevalence of cortical superficial siderosis in a memory clinic population. Neurology, 2014, 82, 698-704.	1.5	71
185	Matrix Metalloproteinases in Alzheimerâ€™s Disease and Concurrent Cerebral Microbleeds. Journal of Alzheimer's Disease, 2015, 48, 711-720.	1.2	71
186	MRI Visual Ratings of Brain Atrophy and White Matter Hyperintensities across the Spectrum of Cognitive Decline Are Differently Affected by Age and Diagnosis. Frontiers in Aging Neuroscience, 2017, 9, 117.	1.7	71
187	Baseline CSF p-tau levels independently predict progression of hippocampal atrophy in Alzheimer disease. Neurology, 2009, 73, 935-940.	1.5	70
188	Single-Subject Gray Matter Graph Properties and Their Relationship with Cognitive Impairment in Early- and Late-Onset Alzheimer's Disease. Brain Connectivity, 2014, 4, 337-346.	0.8	69
189	Gait Speed and Grip Strength Reflect Cognitive Impairment and Are Modestly Related to Incident Cognitive Decline in Memory Clinic Patients With Subjective Cognitive Decline and Mild Cognitive Impairment: Findings From the 4C Study. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2017, 72, 846-854.	1.7	69
190	Magnetic Resonance Imaging Predictors of Cognition in Mild Cognitive Impairment. Archives of Neurology, 2007, 64, 1023.	4.9	67
191	Cognitive Impairment in Alzheimerâ€™s Disease Is Modified by APOE Genotype. Dementia and Geriatric Cognitive Disorders, 2007, 24, 98-103.	0.7	66
192	Specific risk factors for microbleeds and white matter hyperintensities in Alzheimer's disease. Neurobiology of Aging, 2013, 34, 2488-2494.	1.5	66
193	The need for harmonisation and innovation of neuropsychological assessment in neurodegenerative dementias in Europe: consensus document of the Joint Program for Neurodegenerative Diseases Working Group. Alzheimer's Research and Therapy, 2017, 9, 27.	3.0	66
194	Loss of <scp>EEG</scp><scp>N</scp>etwork <scp>E</scp>fficiency <scp>I</scp>s <scp>R</scp>elated to <scp>C</scp>ognitive <scp>I</scp>mpairment in <scp>D</scp>ementia <scp>W</scp>ith <scp>L</scp>ewy <scp>B</scp>odies. Movement Disorders, 2015, 30, 1785-1793.	2.2	65
195	Resting state functional connectivity differences between behavioral variant frontotemporal dementia and Alzheimer's disease. Frontiers in Human Neuroscience, 2015, 9, 474.	1.0	64
196	The association of angiotensin-converting enzyme with biomarkers for Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2014, 6, 27.	3.0	63
197	Cognitive decline in AD and mild cognitive impairment is associated with global brain damage. Neurology, 2002, 59, 874-879.	1.5	62
198	Prognostic Factors for Cognitive Decline After Intracerebral Hemorrhage. Stroke, 2015, 46, 2773-2778.	1.0	61

#	Article	IF	Citations
199	Cerebral Blood Flow and Cognitive Functioning in a Community-Based, Multi-Ethnic Cohort: The SABRE Study. Frontiers in Aging Neuroscience, 2018, 10, 279.	1.7	61
200	Prevalence and Clinical Significance of Epileptiform EEG Discharges in a Large Memory Clinic Cohort. Dementia and Geriatric Cognitive Disorders, 2010, 29, 432-437.	0.7	60
201	Apolipoprotein A1 in Cerebrospinal Fluid and Plasma and Progression to Alzheimerâ€™s Disease in Non-Demented Elderly. Journal of Alzheimer's Disease, 2017, 56, 687-697.	1.2	60
202	Diagnostic impact of CSF biomarkers for Alzheimer's disease inÂaÂtertiary memory clinic. Alzheimer's and Dementia, 2015, 11, 523-532.	0.4	59
203	Cognitive subtypes of probable Alzheimer's disease robustly identified inÂfour cohorts. Alzheimer's and Dementia, 2017, 13, 1226-1236.	0.4	59
204	A neuroimaging approach to capture cognitive reserve: Application to Alzheimer's disease. Human Brain Mapping, 2017, 38, 4703-4715.	1.9	59
205	Application of Machine Learning to Arterial Spin Labeling in Mild Cognitive Impairment and Alzheimer Disease. Radiology, 2016, 281, 865-875.	3.6	58
206	Prevalence of the apolipoprotein E Îµ4 allele in amyloid Î² positive subjects across the spectrum of Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 913-924.	0.4	58
207	Atrophy, hypometabolism and clinical trajectories in patients with amyloid-negative Alzheimerâ€™s disease. Brain, 2016, 139, 2528-2539.	3.7	58
208	Corpus callosum atrophy as a predictor of age-related cognitive and motor impairment: A 3-year follow-up of the LADIS study cohort. Journal of the Neurological Sciences, 2011, 307, 100-105.	0.3	57
209	The Dutch Parelsnoer Institute - Neurodegenerative diseases; methods, design and baseline results. BMC Neurology, 2014, 14, 254.	0.8	57
210	Alzheimer's biomarkers in daily practice (ABIDE) project: Rationale and design. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 6, 143-151.	1.2	57
211	Associations between Patterns of EEG Abnormalities and Diagnosis in a Large Memory Clinic Cohort. Dementia and Geriatric Cognitive Disorders, 2009, 27, 18-23.	0.7	56
212	Molecular imaging in the diagnosis of Alzheimer's disease: visual assessment of [11C]PIB and [18F]FDDNP PET images. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, 882-884.	0.9	56
213	Widespread Disruption of Functional Brain Organization in Early-Onset Alzheimerâ€™s Disease. PLoS ONE, 2014, 9, e102995.	1.1	56
214	Bloodâ€based metabolic signatures in Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 8, 196-207.	1.2	56
215	Small vessel versus large vessel vascular dementia. Journal of Neurology, 2008, 255, 1644-1651.	1.8	55
216	Microbleeds relate to altered amyloid-beta metabolism in Alzheimer's disease. Neurobiology of Aging, 2012, 33, 1011.e1-1011.e9.	1.5	55

#	Article	IF	Citations
217	Clusterin Levels in Plasma Predict Cognitive Decline and Progression to Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2015, 46, 1103-1110.	1.2	55
218	Multitracer model for staging cortical amyloid deposition using PET imaging. Neurology, 2020, 95, e1538-e1553.	1.5	55
219	Serial CSF sampling in Alzheimer's disease: specific versus non-specific markers. Neurobiology of Aging, 2012, 33, 1591-1598.	1.5	52
220	EEG-directed connectivity from posterior brain regions is decreased in dementia with Lewy bodies: a comparison with Alzheimer's disease and controls. Neurobiology of Aging, 2016, 41, 122-129.	1.5	52
221	Gray matter networks and clinical progression in subjects with predementia Alzheimer's disease. Neurobiology of Aging, 2018, 61, 75-81.	1.5	52
222	Diagnostic performance of Elecsys immunoassays for cerebrospinal fluid Alzheimer's disease biomarkers in a nonacademic, multicenter memory clinic cohort: The ABIDE project. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 563-572.	1.2	52
223	Psychosocial Effects of Corona Measures on Patients With Dementia, Mild Cognitive Impairment and Subjective Cognitive Decline. Frontiers in Psychiatry, 2020, 11, 585686.	1.3	52
224	Long-term effects of amyloid, hypometabolism, and atrophy on neuropsychological functions. Neurology, 2014, 82, 1768-1775.	1.5	51
225	Gray matter network disruptions and amyloid beta in cognitively normal adults. Neurobiology of Aging, 2016, 37, 154-160.	1.5	51
226	Applying the ATN scheme in a memory clinic population. Neurology, 2019, 93, e1635-e1646.	1.5	51
227	Diagnostic Value of the CSF Î±-Synuclein Real-Time Quaking-Induced Conversion Assay at the Prodromal MCI Stage of Dementia With Lewy Bodies. Neurology, 2021, 97, e930-e940.	1.5	51
228	Distinct perfusion patterns in Alzheimerâ€™s disease, frontotemporal dementia and dementia with Lewy bodies. European Radiology, 2014, 24, 2326-2333.	2.3	50
229	Alzheimer's disease risk variants modulate endophenotypes in mild cognitive impairment. Alzheimer's and Dementia, 2016, 12, 872-881.	0.4	50
230	Late-Onset Dementia: Structural Brain Damage and Total Cerebral Blood Flow. Radiology, 2005, 236, 990-995.	3.6	49
231	Apolipoprotein E Genotype Influences Presence and Severity of Delusions and Aggressive Behavior in Alzheimer Disease. Dementia and Geriatric Cognitive Disorders, 2007, 23, 42-46.	0.7	49
232	Cerebrospinal fluid biomarkers and cerebral atrophy in distinct clinical variants of probable Alzheimer's disease. Neurobiology of Aging, 2015, 36, 2340-2347.	1.5	49
233	PLD3 variants in population studies. Nature, 2015, 520, E2-E3.	13.7	49
234	Highly specific and ultrasensitive plasma test detects Abeta(1â€“42) and Abeta(1â€“40) in Alzheimerâ€™s disease. Scientific Reports, 2021, 11, 9736.	1.6	49

#	Article	IF	Citations
235	New Research Criteria for the Diagnosis of Alzheimerâ€™s Disease Applied in a Memory Clinic Population. Dementia and Geriatric Cognitive Disorders, 2010, 30, 1-7.	0.7	48
236	Microbleeds, Mortality, and Stroke in Alzheimer Disease. JAMA Neurology, 2015, 72, 539.	4.5	48
237	A Longitudinal Study on Resting State Functional Connectivity in Behavioral Variant Frontotemporal Dementia and Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2016, 55, 521-537.	1.2	48
238	Differences in structural covariance brain networks between behavioral variant frontotemporal dementia and Alzheimer's disease. Human Brain Mapping, 2016, 37, 978-988.	1.9	48
239	Sex differences in CSF biomarkers vary by Alzheimer disease stage and APOE Îµ4 genotype. Neurology, 2020, 95, e2378-e2388.	1.5	48
240	Microbleeds in vascular dementia: Clinical aspects. Experimental Gerontology, 2012, 47, 853-857.	1.2	47
241	Patients' and caregivers' views on conversations and shared decision making in diagnostic testing for Alzheimer's disease: The ABIDE project. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2017, 3, 314-322.	1.8	47
242	Investigation of resting-state EEG functional connectivity in frontotemporal lobar degeneration. Clinical Neurophysiology, 2008, 119, 1732-1738.	0.7	46
243	More Atrophy of Deep Gray Matter Structures in Frontotemporal Dementia Compared to Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 44, 635-647.	1.2	46
244	Clinical phenotype, atrophy, and small vessel disease in APOE Îµ2 carriers with Alzheimer disease. Neurology, 2018, 91, e1851-e1859.	1.5	46
245	Centenarian controls increase variant effect sizes by an average twofold in an extreme caseâ€“extreme control analysis of Alzheimerâ€™s disease. European Journal of Human Genetics, 2019, 27, 244-253.	1.4	46
246	Identification of novel cerebrospinal fluid biomarker candidates for dementia with Lewy bodies: a proteomic approach. Molecular Neurodegeneration, 2020, 15, 36.	4.4	46
247	Measuring Resilience and Resistance in Aging and Alzheimer Disease Using Residual Methods. Neurology, 2021, 97, 474-488.	1.5	46
248	Comparison of the Alzheimerâ€™s Disease Assessment Scale Cognitive Subscale and the Vascular Dementia Assessment Scale in Differentiating Elderly Individuals with Different Degrees of White Matter Changes. Dementia and Geriatric Cognitive Disorders, 2007, 24, 73-81.	0.7	45
249	CSF Biomarkers in Alzheimer's Disease and Controls: Associations with APOE Genotype are Modified by Age. Journal of Alzheimer's Disease, 2009, 16, 601-607.	1.2	45
250	Differential association of [¹¹ C]PIB and [¹⁸ F]FDDNP binding with cognitive impairment. Neurology, 2009, 73, 2079-2085.	1.5	45
251	SUCLG2 identified as both a determinator of CSF AÎ²1â€“42 levels and an attenuator of cognitive decline in Alzheimer's disease. Human Molecular Genetics, 2014, 23, 6644-6658.	1.4	45
252	The Heart-Brain Connection: A Multidisciplinary Approach Targeting a Missing Link in the Pathophysiology of Vascular Cognitive Impairment. Journal of Alzheimer's Disease, 2014, 42, S443-S451.	1.2	45

#	Article	IF	Citations
253	Subjective Memory Complaints in APOE É›4 Carriers are Associated with High Amyloid-Î² Burden. Journal of Alzheimer's Disease, 2016, 49, 1115-1122.	1.2	45
254	A novel quantification-driven proteomic strategy identifies an endogenous peptide of pleiotrophin as a new biomarker of Alzheimerâ€™s disease. Scientific Reports, 2017, 7, 13333.	1.6	45
255	The Missing Link in the Pathophysiology of Vascular Cognitive Impairment: Design of the Heart-Brain Study. Cerebrovascular Diseases Extra, 2018, 7, 140-152.	0.5	44
256	Gray matter network measures are associated with cognitive decline in mild cognitive impairment. Neurobiology of Aging, 2018, 61, 198-206.	1.5	44
257	Application of the ATN classification scheme in a population without dementia: Findings from the EPAD cohort. Alzheimer's and Dementia, 2021, 17, 1189-1204.	0.4	44
258	Neuropsychiatric and Cognitive Symptoms Across the Alzheimer Disease Clinical Spectrum. Neurology, 2021, 97, e1276-e1287.	1.5	44
259	Early onset APOE E4-negative Alzheimerâ€™s disease patients show faster cognitive decline on non-memory domains. European Neuropsychopharmacology, 2015, 25, 1010-1017.	0.3	43
260	7T T2â^—-weighted magnetic resonance imaging reveals cortical phase differences between early- and late-onset Alzheimer's disease. Neurobiology of Aging, 2015, 36, 20-26.	1.5	43
261	Cerebrovascular and amyloid pathology in predementia stages: the relationship with neurodegeneration and cognitive decline. Alzheimer's Research and Therapy, 2017, 9, 101.	3.0	43
262	Precision prevention of Alzheimer's and other dementias: Anticipating future needs in the control of risk factors and implementation of diseaseâ€modifying therapies. Alzheimer's and Dementia, 2020, 16, 1457-1468.	0.4	43
263	EEG abnormalities in early and late onset Alzheimer's disease: understanding heterogeneity. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 67-71.	0.9	42
264	Serum Leptin is not Altered nor Related to Cognitive Decline in Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 44, 809-813.	1.2	42
265	Thinner temporal and parietal cortex is related to incident clinical progression to dementia in patients with subjective cognitive decline. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2016, 5, 43-52.	1.2	42
266	Quantification of Tau Load Using [18F]AV1451 PET. Molecular Imaging and Biology, 2017, 19, 963-971.	1.3	42
267	Cerebral amyloid burden is associated with white matter hyperintensity location in specific posterior white matter regions. Neurobiology of Aging, 2019, 84, 225-234.	1.5	42
268	Cross-cohort generalizability of deep and conventional machine learning for MRI-based diagnosis and prediction of Alzheimerâ€™s disease. NeuroImage: Clinical, 2021, 31, 102712.	1.4	42
269	Transcranial Doppler Blood Flow Assessment in Patients With Mild Heart Failure: Correlates With Neuroimaging and Cognitive Performance. Congestive Heart Failure, 2008, 14, 61-65.	2.0	41
270	Protein Kinase Activity Decreases withÂHigher Braak Stages of Alzheimerâ€™s Disease Pathology. Journal of Alzheimer's Disease, 2016, 49, 927-943.	1.2	41

#	Article	IF	Citations
271	Long-Term Prognostic Implications ofÂPrevious Silent Myocardial Infarction inÂPatients Presenting With AcuteÂMyocardial Infarction. JACC: Cardiovascular Imaging, 2018, 11, 1773-1781.	2.3	41
272	Subjective Cognitive Decline Is Associated With Altered Default Mode Network Connectivity in Individuals With a Family History of Alzheimerâ€™s Disease. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2018, 3, 463-472.	1.1	41
273	Amyloid PET and cognitive decline in cognitively normal individuals: the SCIENCe project. Neurobiology of Aging, 2019, 79, 50-58.	1.5	41
274	Association of CSF, Plasma, and Imaging Markers of Neurodegeneration With Clinical Progression in People With Subjective Cognitive Decline. Neurology, 2022, 98, .	1.5	41
275	Different patterns of cortical gray matter loss over time in behavioral variant frontotemporal dementia and Alzheimer's disease. Neurobiology of Aging, 2016, 38, 21-31.	1.5	40
276	A more randomly organized grey matter network is associated with deteriorating language and global cognition in individuals with subjective cognitive decline. Human Brain Mapping, 2018, 39, 3143-3151.	1.9	40
277	Discordant amyloid-Î² PET and CSF biomarkers and its clinical consequences. Alzheimer's Research and Therapy, 2019, 11, 78.	3.0	40
278	PLCG2 protective variant p.P522R modulates tau pathology and disease progression in patients with mild cognitive impairment. Acta Neuropathologica, 2020, 139, 1025-1044.	3.9	40
279	Spatial-Temporal Patterns of Î²-Amyloid Accumulation. Neurology, 2022, 98, .	1.5	40
280	Additional Value of CSF Amyloid-Î²40 Levels in the Differentiation between FTLD and Control Subjects. Journal of Alzheimer's Disease, 2010, 20, 445-452.	1.2	39
281	Lower cerebral blood flow in subjects with Alzheimer's dementia, mild cognitive impairment, and subjective cognitive decline using twoâ€dimensional phaseâ€contrast magnetic resonance imaging. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 9, 76-83.	1.2	39
282	AÎ²34 is a BACE1-derived degradation intermediate associated with amyloid clearance and Alzheimerâ€™s disease progression. Nature Communications, 2019, 10, 2240.	5.8	39
283	Diagnostic Impact of CSF Biomarkers in a Local Hospital Memory Clinic. Dementia and Geriatric Cognitive Disorders, 2010, 29, 491-497.	0.7	38
284	Joint assessment of white matter integrity, cortical and subcortical atrophy to distinguish AD from behavioral variant FTD: A two-center study. NeuroImage: Clinical, 2015, 9, 418-429.	1.4	38
285	Performance of five automated white matter hyperintensity segmentation methods in a multicenter dataset. Scientific Reports, 2019, 9, 16742.	1.6	38
286	Development and Usability of ADappt: Web-Based Tool to Support Clinicians, Patients, and Caregivers in the Diagnosis of Mild Cognitive Impairment and Alzheimer Disease. JMIR Formative Research, 2019, 3, e13417.	0.7	38
287	Amyloid and its association with default network integrity in Alzheimer's disease. Human Brain Mapping, 2014, 35, 779-791.	1.9	37
288	ABCA7 p.G215S as potential protective factor for Alzheimer's disease. Neurobiology of Aging, 2016, 46, 235.e1-235.e9.	1.5	37

#	Article	IF	Citations
289	Neurogranin as Cerebrospinal Fluid Biomarker for Alzheimer Disease: An Assay Comparison Study. Clinical Chemistry, 2018, 64, 927-937.	1.5	37
290	Amyloid-Î² Load Is Related to Worries, but Not to Severity of Cognitive Complaints in Individuals With Subjective Cognitive Decline: The SCIENCe Project. Frontiers in Aging Neuroscience, 2019, 11, 7.	1.7	37
291	Finding Treatment Effects in Alzheimer Trials in the Face of Disease Progression Heterogeneity. Neurology, 2021, 96, e2673-e2684.	1.5	37
292	The Added Value of 18-Fluorodeoxyglucose-Positron Emission Tomography in the Diagnosis of the Behavioral Variant of Frontotemporal Dementia. American Journal of Alzheimer's Disease and Other Dementias, 2014, 29, 607-613.	0.9	36
293	The Rest-Activity Rhythm and Physical Activity in Early-Onset Dementia. Alzheimer Disease and Associated Disorders, 2015, 29, 45-49.	0.6	36
294	Web-Based Multidomain Lifestyle Programs for Brain Health: Comprehensive Overview and Meta-Analysis. JMIR Mental Health, 2019, 6, e12104.	1.7	36
295	Distribution of APOE Genotypes in a Memory Clinic Cohort. Dementia and Geriatric Cognitive Disorders, 2008, 25, 433-438.	0.7	35
296	Differential Expression of microRNA in Cerebrospinal Fluid as a Potential Novel Biomarker for Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2015, 47, 243-252.	1.2	35
297	Heterogeneous Language Profiles in Patients with Primary Progressive Aphasia due to Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2016, 51, 581-590.	1.2	35
298	Detecting frontotemporal dementia syndromes using MRI biomarkers. NeuroImage: Clinical, 2019, 22, 101711.	1.4	35
299	Modifiable risk factors for dementia and dementia risk profiling. A user manual for Brain Health Servicesâ€”part 2 of 6. Alzheimer's Research and Therapy, 2021, 13, 169.	3.0	35
300	Behavioural and psychological symptoms are not related to white matter hyperintensities and medial temporal lobe atrophy in Alzheimer's disease. International Journal of Geriatric Psychiatry, 2008, 23, 387-392.	1.3	34
301	Young Alzheimer patients show distinct regional changes of oscillatory brain dynamics. Neurobiology of Aging, 2012, 33, 1008.e25-1008.e31.	1.5	34
302	Cerebral white matter changes are associated with abnormalities on neurological examination in non-disabled elderly: the LADIS study. Journal of Neurology, 2013, 260, 1014-1021.	1.8	34
303	The Influence of Co-Morbidity and Frailty on the Clinical Manifestation of Patients with Alzheimer's Disease. Journal of Alzheimer's Disease, 2014, 42, 501-509.	1.2	34
304	The Pitfall of Behavioral Variant Frontotemporal Dementia Mimics DespiteÂMultidisciplinary Application ofÂtheÂFTDC Criteria. Journal of Alzheimer's Disease, 2017, 60, 959-975.	1.2	34
305	Disclosure of amyloid positron emission tomography results to individuals without dementia: a systematic review. Alzheimer's Research and Therapy, 2018, 10, 72.	3.0	34
306	Plasma amyloid is associated with the rate of cognitive decline in cognitively normal elderly: the SCIENCe project. Neurobiology of Aging, 2020, 89, 99-107.	1.5	34

#	Article	IF	Citations
307	MRI measures and progression of cognitive decline in nondemented elderly attending a memory clinic. International Journal of Geriatric Psychiatry, 2005, 20, 1060-1066.	1.3	33
308	Quantitation of brain tissue changes associated with white matter hyperintensities by diffusionâ€weighted and magnetization transfer imaging: The LADIS (leukoaraiosis and disability in the) Tj ETQq0 0 0 rgBT /Overlock 10	1.9	33
309	Apraxia in Mild Cognitive Impairment and Alzheimer's Disease: Validity and Reliability of the Van Heugten Test for Apraxia. Dementia and Geriatric Cognitive Disorders, 2014, 38, 55-64.	0.7	33
310	Directional information flow in patients with Alzheimer's disease. A source-space resting-state MEG study. NeuroImage: Clinical, 2017, 15, 673-681.	1.4	33
311	Single Subject Classification of Alzheimerâ€™s Disease and Behavioral Variant Frontotemporal Dementia Using Anatomical, Diffusion Tensor, and Resting-State Functional Magnetic Resonance Imaging. Journal of Alzheimer's Disease, 2018, 62, 1827-1839.	1.2	33
312	Gray matter T1â€w/T2â€w ratios are higher in Alzheimer's disease. Human Brain Mapping, 2019, 40, 3900-3909.	1.9	33
313	Immune response and endocytosis pathways are associated with the resilience against Alzheimerâ€™s disease. Translational Psychiatry, 2020, 10, 332.	2.4	33
314	The Association Between Biomarkers and Neuropsychiatric Symptoms Across the Alzheimer's Disease Spectrum. American Journal of Geriatric Psychiatry, 2020, 28, 735-744.	0.6	33
315	Prodromal Dementia With Lewy Bodies: Clinical Characterization and Predictors of Progression. Movement Disorders, 2020, 35, 859-867.	2.2	33
316	Validation of the automated method VIENA: An accurate, precise, and robust measure of ventricular enlargement. Human Brain Mapping, 2014, 35, 1101-1110.	1.9	32
317	Predicting progression to dementia in persons with mild cognitive impairment using cerebrospinal fluid markers. Alzheimer's and Dementia, 2017, 13, 903-912.	0.4	32
318	Rare Genetic Variant in SORL1 May Increase Penetrance of Alzheimerâ€™s Disease in a Family with Several Generations of APOE-É›4 Homozygosity. Journal of Alzheimer's Disease, 2017, 56, 63-74.	1.2	32
319	Infratentorial Abnormalities in Vascular Dementia. Stroke, 2006, 37, 105-110.	1.0	31
320	Structural neuroimaging. , 2009, , 58-69.		31
321	Regional atrophy is associated with impairment in distinct cognitive domains in Alzheimer's disease. Alzheimer's and Dementia, 2014, 10, S299-305.	0.4	31
322	Malnutrition and Risk of Structural Brain Changes Seen on Magnetic Resonance Imaging in Older Adults. Journal of the American Geriatrics Society, 2016, 64, 2457-2463.	1.3	31
323	Dietary patterns are related to cognitive functioning in elderly enriched with individuals at increased risk for Alzheimerâ€™s disease. European Journal of Nutrition, 2021, 60, 849-860.	1.8	31
324	Amyloid-Î² misfolding as a plasma biomarker indicates risk for future clinical Alzheimerâ€™s disease in individuals with subjective cognitive decline. Alzheimer's Research and Therapy, 2020, 12, 169.	3.0	31

#	Article	IF	Citations
325	Association of Rare APOE Missense Variants V236E and R251G With Risk of Alzheimer Disease. JAMA Neurology, 2022, 79, 652.	4.5	31
326	Joint Effect of Hypertension and APOE Genotype on CSF Biomarkers for Alzheimer's Disease. Journal of Alzheimer's Disease, 2010, 20, 1083-1090.	1.2	30
327	Building a New Paradigm for the Early Recognition of Behavioral Variant Frontotemporal Dementia: Late Onset Frontal Lobe Syndrome Study. American Journal of Geriatric Psychiatry, 2014, 22, 735-740.	0.6	30
328	Trajectories and Determinants of Quality of Life in Dementia with Lewy Bodies and Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2019, 70, 389-397.	1.2	30
329	Personalized risk for clinical progression in cognitively normal subjectsâ€”the ABIDE project. Alzheimer's Research and Therapy, 2019, 11, 33.	3.0	30
330	Brain amyloid Î², cerebral small vessel disease, and cognition. Neurology, 2020, 95, e2845-e2853.	1.5	30
331	Identifying Sensitive Measures of Cognitive Decline at Different Clinical Stages of Alzheimerâ€™s Disease. Journal of the International Neuropsychological Society, 2021, 27, 426-438.	1.2	30
332	Data-Driven Differential Diagnosis of Dementia Using Multiclass Disease State Index Classifier. Frontiers in Aging Neuroscience, 2018, 10, 111.	1.7	29
333	Gray Matter Network Disruptions and Regional Amyloid Beta in Cognitively Normal Adults. Frontiers in Aging Neuroscience, 2018, 10, 67.	1.7	29
334	Frequent Cognitive Impairment in Patients With Disorders Along the Heart-Brain Axis. Stroke, 2019, 50, 3369-3375.	1.0	29
335	Regional [18F]flortaucipir PET is more closely associated with disease severity than CSF p-tau in Alzheimerâ€™s disease. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2866-2878.	3.3	29
336	Vascular Cognitive Impairment in a Memory Clinic Population: Rationale and Design of the â€œUtrecht-Amsterdam Clinical Features and Prognosis in Vascular Cognitive Impairmentâ€•(TRACE-VCI) Study. JMIR Research Protocols, 2017, 6, e60.	0.5	29
337	Magnetization transfer imaging of gray and white matter in mild cognitive impairment and Alzheimer's disease. Neurobiology of Aging, 2006, 27, 1757-1762.	1.5	28
338	Brain volume and white matter hyperintensities as determinants of cerebral blood flow in Alzheimer's disease. Neurobiology of Aging, 2014, 35, 2665-2670.	1.5	28
339	Diagnostic dilemmas in Alzheimer's disease: Room for shared decision making. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2017, 3, 301-304.	1.8	28
340	Plasma Protein Biomarkers for the Prediction of CSF Amyloid and Tau and [18F]-Flutemetamol PET Scan Result. Frontiers in Aging Neuroscience, 2018, 10, 409.	1.7	28
341	Smaller medial temporal lobe volumes in individuals with subjective cognitive decline and biomarker evidence of Alzheimer's diseaseâ€”Data from three memory clinic studies. Alzheimer's and Dementia, 2019, 15, 185-193.	0.4	28
342	Tau pathology and relative cerebral blood flow are independently associated with cognition in Alzheimerâ€™s disease. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 3165-3175.	3.3	28

#	Article	IF	Citations
343	Differential diagnostic performance of a panel of plasma biomarkers for different types of dementia. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2022, 14, .	1.2	28
344	Neuropsychological Correlates of MRI Measures in the Continuum of Cognitive Decline at Old Age. Dementia and Geriatric Cognitive Disorders, 2005, 20, 82-88.	0.7	27
345	Shifting Paradigms in Dementia: Toward Stratification of Diagnosis and Treatment Using MRI. Annals of the New York Academy of Sciences, 2007, 1097, 215-224.	1.8	27
346	Serum Amyloid P Component as a Biomarker in Mild Cognitive Impairment and Alzheimerâ€™s Disease. Dementia and Geriatric Cognitive Disorders, 2008, 26, 522-527.	0.7	27
347	Quantitative regional validation of the visual rating scale for posterior cortical atrophy. European Radiology, 2014, 24, 397-404.	2.3	27
348	The influence of genetic variants in SORL1 gene on the manifestation of Alzheimer's disease. Neurobiology of Aging, 2015, 36, 1605.e13-1605.e20.	1.5	27
349	Association of Cerebrospinal Fluid (CSF) Insulin with Cognitive Performance and CSF Biomarkers of Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2017, 61, 309-320.	1.2	27
350	Modeling grey matter atrophy as a function of time, aging or cognitive decline show different anatomical patterns in Alzheimer's disease. NeuroImage: Clinical, 2019, 22, 101786.	1.4	27
351	Dataâ€driven approaches for tauâ€PET imaging biomarkers in Alzheimer's disease. Human Brain Mapping, 2019, 40, 638-651.	1.9	27
352	EEG functional connectivity and ApoE genotype in Alzheimerâ€™s disease and controls. Clinical Neurophysiology, 2008, 119, 2727-2732.	0.7	26
353	Identifying bvFTD Within the Wide Spectrum of Late Onset Frontal Lobe Syndrome: A Clinical Approach. American Journal of Geriatric Psychiatry, 2015, 23, 1056-1066.	0.6	26
354	CSF ApoE predicts clinical progression in nondemented APOEÎµ4 carriers. Neurobiology of Aging, 2017, 57, 186-194.	1.5	26
355	VGF Peptides in Cerebrospinal Fluid of Patients with Dementia with Lewy Bodies. International Journal of Molecular Sciences, 2019, 20, 4674.	1.8	26
356	Brain Health Services: organization, structure, and challenges for implementation. A user manual for Brain Health Servicesâ€”part 1 of 6. Alzheimer's Research and Therapy, 2021, 13, 168.	3.0	26
357	Neuropsychological Predictors of Dementia in a Three-Year Follow-Up Period: Data from the LADIS Study. Dementia and Geriatric Cognitive Disorders, 2010, 29, 325-334.	0.7	25
358	Discriminatory and predictive capabilities of enzymeâ€linked immunosorbent assay and multiplex platforms in a longitudinal Alzheimer's disease study. Alzheimer's and Dementia, 2013, 9, 276-283.	0.4	25
359	Altered distribution of the EphA4 kinase in hippocampal brain tissue of patients with Alzheimerâ€™s disease correlates with pathology. Acta Neuropathologica Communications, 2014, 2, 79.	2.4	25
360	The structure of the geriatric depressed brain and response to electroconvulsive therapy. Psychiatry Research - Neuroimaging, 2014, 222, 1-9.	0.9	25

#	Article	IF	Citations
361	Amyloid-independent atrophy patterns predict time to progression to dementia in mild cognitive impairment. Alzheimer's Research and Therapy, 2017, 9, 73.	3.0	25
362	Associations of AD Biomarkers and Cognitive Performance with Nutritional Status: The NUDAD Project. Nutrients, 2019, 11, 1161.	1.7	25
363	CCL23: A Chemokine Associated with Progression from Mild Cognitive Impairment to Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2020, 73, 1585-1595.	1.2	25
364	Contribution of Gut Microbiota to Immunological Changes in Alzheimerâ€™s Disease. Frontiers in Immunology, 2021, 12, 683068.	2.2	25
365	Considerations regarding a diagnosis of Alzheimerâ€™s disease before dementia: a systematic review. Alzheimer's Research and Therapy, 2022, 14, 31.	3.0	25
366	Episodic memory and the medial temporal lobe: not all it seems. Evidence from the temporal variants of frontotemporal dementia. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 1145-1148.	0.9	24
367	Disturbed oscillatory brain dynamics in subcortical ischemic vascular dementia. BMC Neuroscience, 2012, 13, 85.	0.8	24
368	Comparison of Simplified Parametric Methods for Visual Interpretation of ¹¹C-Pittsburgh Compound-B PET Images. Journal of Nuclear Medicine, 2014, 55, 1305-1307.	2.8	24
369	Clinical relevance of acute cerebral microinfarcts in vascular cognitive impairment. Neurology, 2019, 92, e1558-e1566.	1.5	24
370	Clinicians' views on conversations and shared decision making in diagnostic testing for Alzheimer's disease: The ABIDE project. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2017, 3, 305-313.	1.8	23
371	Thinner cortex in patients with subjective cognitive decline is associated with steeper decline of memory. Neurobiology of Aging, 2018, 61, 238-244.	1.5	23
372	Hypometabolism of the posterior cingulate cortex is not restricted to Alzheimer's disease. NeuroImage: Clinical, 2018, 19, 625-632.	1.4	23
373	Preâ€amyloid stage of Alzheimer's disease in cognitively normal individuals. Annals of Clinical and Translational Neurology, 2018, 5, 1037-1047.	1.7	23
374	Clinicianâ€patient communication during the diagnostic workup: The ABIDE project. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 520-528.	1.2	23
375	Amyloid-Î² peptides in cerebrospinal fluid of patients with dementia with Lewy bodies. Alzheimer's Research and Therapy, 2019, 11, 83.	3.0	23
376	Impact of a clinical decision support tool on prediction of progression in early-stage dementia: a prospective validation study. Alzheimer's Research and Therapy, 2019, 11, 25.	3.0	23
377	Automatically computed rating scales from MRI for patients with cognitive disorders. European Radiology, 2019, 29, 4937-4947.	2.3	23
378	Impact of a Clinical Decision Support Tool on Dementia Diagnostics in Memory Clinics: The PredictND Validation Study. Current Alzheimer Research, 2019, 16, 91-101.	0.7	23

#	Article	IF	Citations
379	Testâ€“retest repeatability of [¹⁸F]Flortaucipir PET in Alzheimerâ€™s disease and cognitively normal individuals. Journal of Cerebral Blood Flow and Metabolism, 2020, 40, 2464-2474.	2.4	23
380	Sex-specific associations with cerebrospinal fluid biomarkers in dementia with Lewy bodies. Alzheimer's Research and Therapy, 2020, 12, 44.	3.0	23
381	The natural history of primary progressive aphasia: beyond aphasia. Journal of Neurology, 2022, 269, 1375-1385.	1.8	23
382	Hippocampal volume loss and Alzheimer disease progression. Nature Reviews Neurology, 2009, 5, 361-362.	4.9	22
383	A prediction model to calculate probability of Alzheimer's disease using cerebrospinal fluid biomarkers. Alzheimer's and Dementia, 2013, 9, 262-268.	0.4	22
384	Survival in memory clinic cohort is short, even in young-onset dementia. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 726-728.	0.9	22
385	Quantification of [¹⁸F]florbetapir: A testâ€“retest tracer kinetic modelling study. Journal of Cerebral Blood Flow and Metabolism, 2019, 39, 2172-2180.	2.4	22
386	High amyloid burden is associated with fewer specific words during spontaneous speech in individuals with subjective cognitive decline. Neuropsychologia, 2019, 131, 184-192.	0.7	22
387	Characteristics of subjective cognitive decline associated with amyloid positivity. Alzheimer's and Dementia, 2022, 18, 1832-1845.	0.4	22
388	Evaluation of Intrathecal Serum Amyloid P (SAP) and C-Reactive Protein (CRP) Synthesis in Alzheimer's Disease with the Use of Index Values. Journal of Alzheimer's Disease, 2011, 22, 1073-1079.	1.2	21
389	EEG Abnormalities Are Associated with Different Cognitive Profiles in Alzheimerâ€™s Disease. Dementia and Geriatric Cognitive Disorders, 2011, 31, 1-6.	0.7	21
390	Decreased mRNA expression of CCL5 [RANTES] in Alzheimer's disease blood samples. Clinical Chemistry and Laboratory Medicine, 2012, 50, 61-5.	1.4	21
391	Associations between Magnetic Resonance Imaging Measures and Neuropsychological Impairment in Early and Late Onset Alzheimer's Disease. Journal of Alzheimer's Disease, 2013, 35, 169-178.	1.2	21
392	Predictors of Progression from Mild Cognitive Impairment to Dementia in the Placebo-Arm of a Clinical Trial Population. Journal of Alzheimer's Disease, 2013, 36, 79-85.	1.2	21
393	Progression to dementia in memory clinic patients without dementia. Neurology, 2013, 81, 1342-1349.	1.5	21
394	Hypertensive Disorders of Pregnancy Appear Not to Be Associated with Alzheimer's Disease Later in Life. Dementia and Geriatric Cognitive Disorders Extra, 2015, 5, 375-385.	0.6	21
395	Clinical heterogeneity in familial Alzheimerâ€™s disease. Lancet Neurology, The, 2016, 15, 1296-1298.	4.9	21
396	Effect of longâ€term storage in biobanks on cerebrospinal fluid biomarker AÎ²_{1â€42}, Tâ€tau, and Pâ€tau values. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 8, 45-50.	1.2	21

#	Article	IF	Citations
397	Vascular Endothelial Growth Factor remains unchanged in cerebrospinal fluid of patients with Alzheimerâ€™s disease and vascular dementia. Alzheimer's Research and Therapy, 2018, 10, 58.	3.0	21
398	Disease trajectories in behavioural variant frontotemporal dementia, primary psychiatric and other neurodegenerative disorders presenting with behavioural change. Journal of Psychiatric Research, 2018, 104, 183-191.	1.5	21
399	PET and CSF amyloid-Î² status are differently predicted by patient features: information from discordant cases. Alzheimer's Research and Therapy, 2019, 11, 100.	3.0	21
400	Olfactory and gustatory functioning and food preferences of patients with Alzheimerâ€™s disease and mild cognitive impairment compared to controls: the NUDAD project. Journal of Neurology, 2020, 267, 144-152.	1.8	21
401	A Suboptimal Diet Is Associated with Poorer Cognition: The NUDAD Project. Nutrients, 2020, 12, 703.	1.7	21
402	Characterization of symptoms and determinants of disease burden in dementia with Lewy bodies: DEvELOP design and baseline results. Alzheimer's Research and Therapy, 2021, 13, 53.	3.0	21
403	Dementia risk communication. A user manual for Brain Health Servicesâ€”part 3 of 6. Alzheimer's Research and Therapy, 2021, 13, 170.	3.0	21
404	Lobar Distribution of Changes in Gray Matter and White Matter in Memory Clinic Patients: Detected Using Magnetization Transfer Imaging. American Journal of Neuroradiology, 2007, 28, 1938-1942.	1.2	20
405	Disturbed phase relations in white matter hyperintensity based vascular dementia: An EEG directed connectivity study. Clinical Neurophysiology, 2015, 126, 497-504.	0.7	20
406	Low normal cerebrospinal fluid AÎ²42 levels predict clinical progression in nondemented subjects. Annals of Neurology, 2017, 81, 749-753.	2.8	20
407	Disease-related determinants are associated with mortality in dementia due to Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2018, 10, 23.	3.0	20
408	European Prevention of Alzheimer's Dementia Registry: Recruitment and prescreening approach for a longitudinal cohort and prevention trials. Alzheimer's and Dementia, 2018, 14, 837-842.	0.4	20
409	Disease Course Varies According to Age and Symptom Length in Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2018, 64, 631-642.	1.2	20
410	Communicating uncertainties when disclosing diagnostic test results for (Alzheimer's) dementia in the memory clinic: The ABIDE project. Health Expectations, 2020, 23, 52-62.	1.1	20
411	Polygenic Risk Score of Longevity Predicts Longer Survival Across an Age Continuum. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2021, 76, 750-759.	1.7	20
412	Clinical Characteristics of Patients With Frontotemporal Dementia With and Without Lobar Atrophy on MRI. Alzheimer Disease and Associated Disorders, 2010, 24, 242-247.	0.6	19
413	Alzheimer's disease patients not carrying the apolipoprotein E Îµ4 allele show more severe slowing of oscillatory brain activity. Neurobiology of Aging, 2013, 34, 2158-2163.	1.5	19
414	Cognitive correlates of cerebrospinal fluid biomarkers in frontotemporal dementia. , 2013, 9, 269-275.		19

#	Article	IF	Citations
415	Increase in Cerebrospinal Fluid F2-Isoprostanes is Related to Cognitive Decline in APOE Îµ4 Carriers. Journal of Alzheimer's Disease, 2013, 36, 563-570.	1.2	19
416	The metabolic syndrome in a memory clinic population: Relation with clinical profile and prognosis. Journal of the Neurological Sciences, 2015, 351, 18-23.	0.3	19
417	Pseudo-healthy Image Synthesis for White Matter Lesion Segmentation. Lecture Notes in Computer Science, 2016, , 87-96.	1.0	19
418	Nutrients required for phospholipid synthesis are lower in blood and cerebrospinal fluid in mild cognitive impairment and Alzheimer's disease dementia. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 8, 139-146.	1.2	19
419	Evaluating combinations of diagnostic tests to discriminate different dementia types. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 509-518.	1.2	19
420	Latent atrophy factors related to phenotypical variants of posterior cortical atrophy. Neurology, 2020, 95, e1672-e1685.	1.5	19
421	Cliniciansâ€™ communication with patients receiving a MCI diagnosis: The ABIDE project. PLoS ONE, 2020, 15, e0227282.	1.1	19
422	Plasma amyloid-Î² oligomerization assay as a pre-screening test for amyloid status. Alzheimer's Research and Therapy, 2021, 13, 133.	3.0	19
423	No Evidence for Additional Bloodâ€“Brain Barrier P-Glycoprotein Dysfunction in Alzheimer's Disease Patients with Microbleeds. Journal of Cerebral Blood Flow and Metabolism, 2012, 32, 1468-1471.	2.4	18
424	Clinical aspects of microbleeds in Alzheimer's disease. Journal of the Neurological Sciences, 2012, 322, 56-58.	0.3	18
425	Angiotensin-Converting Enzyme in Cerebrospinal Fluid and Risk of Brain Atrophy. Journal of Alzheimer's Disease, 2015, 44, 153-162.	1.2	18
426	Screening for Mild Cognitive Impairment and Dementia with Automated, Anonymous Online and Telephone Cognitive Self-Tests. Journal of Alzheimer's Disease, 2017, 56, 249-259.	1.2	18
427	Time Trend in Persistent Cognitive Decline: Results From the Longitudinal Aging Study Amsterdam. Journals of Gerontology - Series B Psychological Sciences and Social Sciences, 2018, 73, S57-S64.	2.4	18
428	Contactin-2, a synaptic and axonal protein, is reduced in cerebrospinal fluid and brain tissue in Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2018, 10, 52.	3.0	18
429	Orthostatic Hypotension: An Important Risk Factor for Clinical Progression to Mild Cognitive Impairment or Dementia. The Amsterdam Dementia Cohort. Journal of Alzheimer's Disease, 2019, 71, 317-325.	1.2	18
430	Assessment of the appropriate use criteria for amyloid PET in an unselected memory clinic cohort: The ABIDE project. Alzheimer's and Dementia, 2019, 15, 1458-1467.	0.4	18
431	Energy intake and expenditure in patients with Alzheimerâ€™s disease and mild cognitive impairment: the NUDAD project. Alzheimer's Research and Therapy, 2020, 12, 116.	3.0	18
432	Hypertensive Exposure Markers by MRI in Relation to Cerebral Small Vessel Disease and Cognitive Impairment. JACC: Cardiovascular Imaging, 2021, 14, 176-185.	2.3	18

#	Article	IF	Citations
433	Four subgroups based on tau levels in Alzheimerâ€™s disease observed in two independent cohorts. Alzheimer's Research and Therapy, 2021, 13, 2.	3.0	18
434	Outcomes of clinical utility in amyloid-PET studies: state of art and future perspectives. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2157-2168.	3.3	18
435	Dysglycemia, brain volume and vascular lesions on MRI in a memory clinic population. Journal of Diabetes and Its Complications, 2014, 28, 85-90.	1.2	17
436	Actigraphic Motor Activity in Mild Cognitive Impairment Patients Carrying Out Short Functional Activity Tasks: Comparison between Mild Cognitive Impairment with and without Depressive Symptoms. Journal of Alzheimer's Disease, 2014, 40, 869-875.	1.2	17
437	A profile of The Clinical Course of Cognition and Comorbidity in Mild Cognitive Impairment and Dementia Study (The 4C study): two complementary longitudinal, clinical cohorts in the Netherlands. BMC Neurology, 2016, 16, 242.	0.8	17
438	Energy and Protein Intake of Alzheimer's Disease Patients Compared to Cognitively Normal Controls: Systematic Review. Journal of the American Medical Directors Association, 2019, 20, 14-21.	1.2	17
439	Nature and implications of sex differences in AD pathology. Nature Reviews Neurology, 2019, 15, 6-8.	4.9	17
440	CDH6 and HAGH protein levels in plasma associate with Alzheimerâ€™s disease in APOE Îµ4 carriers. Scientific Reports, 2020, 10, 8233.	1.6	17
441	Arylesterase Activity of Paraoxonase-1 in Serum and Cerebrospinal Fluid of Patients with Alzheimerâ€™s Disease and Vascular Dementia. Antioxidants, 2020, 9, 456.	2.2	17
442	Circulating metabolites are associated with brain atrophy and white matter hyperintensities. Alzheimer's and Dementia, 2021, 17, 205-214.	0.4	17
443	Specific Nutritional Biomarker Profiles in Mild Cognitive Impairment and Subjective Cognitive Decline Are Associated With Clinical Progression: The NUDAD Project. Journal of the American Medical Directors Association, 2020, 21, 1513.e1-1513.e17.	1.2	17
444	Association of Education and Intracranial Volume With Cognitive Trajectories and Mortality Rates Across the Alzheimer Disease Continuum. Neurology, 2022, 98, .	1.5	17
445	Usefulness of Longitudinal Measurements of Î²-Amyloid1â€“42 in Cerebrospinal Fluid of Patients with Various Cognitive and Neurologic Disorders. Clinical Chemistry, 2006, 52, 1604-1606.	1.5	16
446	Variability in longitudinal cerebrospinal fluid tau and phosphorylated tau measurements. Clinical Chemistry and Laboratory Medicine, 2008, 46, 1300-4.	1.4	16
447	Translational Research in Genomics of Alzheimer's Disease: A Review of Current Practice and Future Perspectives. Journal of Alzheimer's Disease, 2010, 20, 967-980.	1.2	16
448	Neurological abnormalities predict disability: the LADIS (Leukoaraiosis And DISability) study. Journal of Neurology, 2014, 261, 1160-1169.	1.8	16
449	White Matter Hyperintensities Potentiate Hippocampal Volume Reduction in Non-Demented Older Individuals with Abnormal Amyloid-Î². Journal of Alzheimer's Disease, 2016, 55, 333-342.	1.2	16
450	The Impact of Frailty and Comorbidity on Institutionalization and Mortality in Persons With Dementia: A Prospective Cohort Study. Journal of the American Medical Directors Association, 2019, 20, 165-170.e2.	1.2	16

#	Article	IF	Citations
451	ABIDE Delphi study: topics to discuss in diagnostic consultations in memory clinics. Alzheimer's Research and Therapy, 2019, 11, 77.	3.0	16
452	The Clinical Phenotype of Vascular Cognitive Impairment in Patients with Type 2 Diabetes Mellitus. Journal of Alzheimer's Disease, 2019, 68, 311-322.	1.2	16
453	Classification of negative and positive 18F-florbetapir brain PET studies in subjective cognitive decline patients using a convolutional neural network. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 721-728.	3.3	16
454	Risk of dementia in APOE Îµ4 carriers is mitigated by a polygenic risk score. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12229.	1.2	16
455	[¹⁸ F]Flortaucipir PET Across Various MAPT Mutations in Presymptomatic and Symptomatic Carriers. Neurology, 2021, 97, e1017-e1030.	1.5	16
456	Detection of contactin-2 in cerebrospinal fluid (CSF) of patients with Alzheimer's disease using Fluorescence Correlation Spectroscopy (FCS). Clinical Biochemistry, 2017, 50, 1061-1066.	0.8	16
457	Improving the Accuracy and Precision of Cognitive Testing in Mild Dementia. Journal of the International Neuropsychological Society, 2012, 18, 314-322.	1.2	15
458	Design of the ExCersionâ€VCI study: The effect of aerobic exercise on cerebral perfusion in patients with vascular cognitive impairment. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2017, 3, 157-165.	1.8	15
459	Cerebral blood flow and cognitive functioning in patients with disorders along the heartâ€“brain axis. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2020, 6, e12034.	1.8	15
460	Identifying relevant outcomes in the progression of Alzheimer's disease; what do patients and care partners want to know about prognosis?. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2021, 7, e12189.	1.8	15
461	Study protocol: EXERcise and Cognition In Sedentary adults with Early-ONset dementia (EXERCISE-ON). BMC Neurology, 2012, 12, 75.	0.8	14
462	Integrating Biomarkers for Underlying Alzheimerâ€™s Disease in Mild Cognitive Impairment in Daily Practice: Comparison of a Clinical Decision Support System with Individual Biomarkers. Journal of Alzheimer's Disease, 2016, 50, 261-270.	1.2	14
463	Prominent Non-Memory Deficits in Alzheimerâ€™s Disease Are Associated with Faster Disease Progression. Journal of Alzheimer's Disease, 2018, 65, 1029-1039.	1.2	14
464	Decision tree supports the interpretation of CSF biomarkers in Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 1-9.	1.2	14
465	Contactin-1 Is Reduced in Cerebrospinal Fluid of Parkinsonâ€™s Disease Patients and Is Present within Lewy Bodies. Biomolecules, 2020, 10, 1177.	1.8	14
466	Tau PET and relative cerebral blood flow in dementia with Lewy bodies: A PET study. NeuroImage: Clinical, 2020, 28, 102504.	1.4	14
467	Decline in cognitively complex everyday activities accelerates along the Alzheimerâ€™s disease continuum. Alzheimer's Research and Therapy, 2020, 12, 138.	3.0	14
468	Multiple Diagnostic Tests Are Needed to Assess Multiple Causes of Dementia. Archives of Neurology, 2006, 63, 144.	4.9	14

#	Article	IF	Citations
469	Single-subject gray matter networks predict future cortical atrophy in preclinical Alzheimer's disease. Neurobiology of Aging, 2020, 94, 71-80.	1.5	14
470	Gait Disturbances are Associated with Increased Cognitive Impairment and Cerebrospinal Fluid Tau Levels in a Memory Clinic Cohort. Journal of Alzheimer's Disease, 2020, 76, 1061-1070.	1.2	13
471	Differential patterns of gray matter volumes and associated gene expression profiles in cognitively-defined Alzheimerâ€™s disease subgroups. NeuroImage: Clinical, 2021, 30, 102660.	1.4	13
472	The protective gene dose effect of the APOEÎµ2 allele on gray matter volume in cognitively unimpaired individuals. Alzheimer's and Dementia, 2022, 18, 1383-1395.	0.4	13
473	Carotid and Basilar Artery Wall Shear Stress in Alzheimerâ€™s Disease and Mild Cognitive Impairment. Dementia and Geriatric Cognitive Disorders, 2009, 28, 220-224.	0.7	12
474	Progression from MCI to AD: Predictive value of CSF AÎ²42 is modified by APOE genotype. Neurobiology of Aging, 2011, 32, 1372-1378.	1.5	12
475	Cortical phase changes measured using 7â€T MRI in subjects with subjective cognitive impairment, and their association with cognitive function. NMR in Biomedicine, 2016, 29, 1289-1294.	1.6	12
476	Impact of Imaging and Cerebrospinal Fluid Biomarkers on Behavioral Variant Frontotemporal Dementia Diagnosis within a Late-Onset Frontal Lobe Syndrome Cohort. Dementia and Geriatric Cognitive Disorders, 2016, 41, 16-26.	0.7	12
477	Lumbar puncture in patients with neurologic conditions. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 8, 108-110.	1.2	12
478	Analysis of C9orf72 repeat expansions in a large international cohort of dementia with Lewy bodies. Neurobiology of Aging, 2017, 49, 214.e13-214.e15.	1.5	12
479	ApoE and clusterin CSF levels influence associations between APOEÂgenotype and changes in CSF tau, but not CSF AÎ²42, levels inÂnon-demented elderly. Neurobiology of Aging, 2019, 79, 101-109.	1.5	12
480	Identifying a task-invariant cognitive reserve network using task potency. NeuroImage, 2020, 210, 116593.	2.1	12
481	Serum and cerebrospinal fluid Neutrophil gelatinase-associated lipocalin (NGAL) levels as biomarkers for the conversion from mild cognitive impairment to Alzheimer's disease dementia. Neurobiology of Aging, 2021, 107, 1-10.	1.5	12
482	Identifying best practices for disclosure of amyloid imaging results: A randomized controlled trial. Alzheimer's and Dementia, 2023, 19, 285-295.	0.4	12
483	Use of laboratory and imaging investigations in dementia. Journal of Neurology, Neurosurgery and Psychiatry, 2005, 76, v45-v52.	0.9	11
484	Glycemia and Levels of Cerebrospinal Fluid Amyloid and Tau in Patients Attending a Memory Clinic. Journal of the American Geriatrics Society, 2010, 58, 1318-1321.	1.3	11
485	Correcting for the Absence of a Gold Standard Improves Diagnostic Accuracy ofÂBiomarkers in Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2015, 46, 889-899.	1.2	11
486	Standard biobanking conditions prevent evaporation of body fluid samples. Clinica Chimica Acta, 2015, 442, 141-145.	0.5	11

#	Article	IF	Citations
487	Wishes and preferences for an online lifestyle program for brain healthâ€"A mixed methods study. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2018, 4, 141-149.	1.8	11
488	Prognostic value of Alzheimerâ€™s biomarkers in mild cognitive impairment: the effect of age at onset. Journal of Neurology, 2019, 266, 2535-2545.	1.8	11
489	ASSOCIATION BETWEEN VITAMIN B6 AND WHITE MATTER HYPERINTENSITIES IN PATIENTS WITH ALZHEIMER'S DISEASE NOT MEDIATED BY HOMOCYSTEINE METABOLISM. Journal of the American Geriatrics Society, 2007, 55, 956-958.	1.3	10
490	Mutation frequency of PRKAR1B and the major familial dementia genes in a Dutch early onset dementia cohort. Journal of Neurology, 2014, 261, 2085-2092.	1.8	10
491	Dietary Patterns Are Related to Clinical Characteristics in Memory Clinic Patients with Subjective Cognitive Decline: The SCIENCe Project. Nutrients, 2019, 11, 1057.	1.7	10
492	Methylphenidate and galantamine in patients with vascular cognitive impairmentâ€“the proof-of-principle study STREAM-VCI. Alzheimer's Research and Therapy, 2020, 12, 10.	3.0	10
493	Nutritional Status Is Associated With Clinical Progression in Alzheimer's Disease: The NUDAD Project. Journal of the American Medical Directors Association, 2023, 24, 638-644.e1.	1.2	10
494	Repeatability of parametric methods for [¹⁸F]florbetapir imaging in Alzheimerâ€™s disease and healthy controls: A testâ€“retest study. Journal of Cerebral Blood Flow and Metabolism, 2021, 41, 569-578.	2.4	10
495	Effect of Shortening the Scan Duration on Quantitative Accuracy of [18F]Flortaucipir Studies. Molecular Imaging and Biology, 2021, 23, 604-613.	1.3	10
496	The Right Temporal Variant of Frontotemporal Dementia Is Not Genetically Sporadic: A Case Series. Journal of Alzheimer's Disease, 2021, 79, 1195-1201.	1.2	10
497	Genetics Contributes to Concomitant Pathology and Clinical Presentation in Dementia with Lewy Bodies. Journal of Alzheimer's Disease, 2021, 83, 269-279.	1.2	10
498	Grey matter network trajectories across the Alzheimerâ€™s disease continuum and relation to cognition. Brain Communications, 2020, 2, fcaa177.	1.5	10
499	Association of the ATN Research Framework With Clinical Profile, Cognitive Decline, and Mortality in Patients With Dementia With Lewy Bodies. Neurology, 2022, 98, .	1.5	10
500	Cerebral atrophy in elderly with subjective memory complaints. Journal of Magnetic Resonance Imaging, 2013, 38, 358-364.	1.9	9
501	Pre-analytical stability of novel cerebrospinal fluid biomarkers. Clinica Chimica Acta, 2019, 497, 204-211.	0.5	9
502	Assessing the Pre-Analytical Stability of Small-Molecule Metabolites in Cerebrospinal Fluid Using Direct-Infusion Metabolomics. Metabolites, 2019, 9, 236.	1.3	9
503	cCOG: A webâ€based cognitive test tool for detecting neurodegenerative disorders. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12083.	1.2	9
504	Nutritional status and structural brain changes in Alzheimer's disease: The NUDAD project. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12063.	1.2	9

#	Article	IF	Citations
505	Amyloidâ€Î², cortical thickness, and subsequent cognitive decline in cognitively normal oldestâ€old. Annals of Clinical and Translational Neurology, 2021, 8, 348-358.	1.7	9
506	Differential trajectories of hypometabolism across cognitively-defined Alzheimerâ€™s disease subgroups. NeuroImage: Clinical, 2021, 31, 102725.	1.4	9
507	What patients want to know, and what we actually tell them: The ABIDE project. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2020, 6, e12113.	1.8	9
508	Impact of white matter hyperintensity location on depressive symptoms in memory-clinic patients: a lesionâ€“symptom mapping study. Journal of Psychiatry and Neuroscience, 2019, 44, E1-E10.	1.4	9
509	Computerâ€assisted prediction of clinical progression in the earliest stages of AD. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 726-736.	1.2	8
510	Added value of amyloid PET in individualized risk predictions for MCI patients. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 529-537.	1.2	8
511	Why Is Amyloid-Î² PET Requested After Performing CSF Biomarkers?. Journal of Alzheimer's Disease, 2020, 73, 559-569.	1.2	8
512	Clinical Phenotypes of Behavioral Variant Frontotemporal Dementia by Age at Onset. Journal of Alzheimer's Disease, 2021, 82, 381-390.	1.2	8
513	Differential associations between neocortical tau pathology and blood flow with cognitive deficits in early-onset vs late-onset Alzheimerâ€™s disease. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 1951-1963.	3.3	8
514	Frontal lobe damage and thalamic volume changes. NeuroReport, 2000, 11, 3039-3041.	0.6	7
515	The effect of amyloid pathology and glucose metabolism on cortical volume loss over time in Alzheimerâ€™s disease. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 1190-8.	3.3	7
516	Combinations of Service Use Types of People With Early Cognitive Disorders. Journal of the American Medical Directors Association, 2016, 17, 620-625.	1.2	7
517	Microbleeds are associated with depressive symptoms in Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 112-120.	1.2	7
518	Repeat length variations in ATXN1 and AR modify disease expression in Alzheimer's disease. Neurobiology of Aging, 2019, 73, 230.e9-230.e17.	1.5	7
519	Profound regional spectral, connectivity, and network changes reflect visual deficits in posterior cortical atrophy: an EEG study. Neurobiology of Aging, 2020, 96, 1-11.	1.5	7
520	Small vessel disease lesion type and brain atrophy: The role of coâ€occurring amyloid. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12060.	1.2	7
521	Nonâ€memory cognitive symptom development in Alzheimer's disease. European Journal of Neurology, 2020, 27, 995-1002.	1.7	7
522	Selection of memory clinic patients for CSF biomarker assessment can be restricted to a quarter of cases by using computerized decision support, without compromising diagnostic accuracy. PLoS ONE, 2020, 15, e0226784.	1.1	7

#	Article	IF	Citations
523	LDL cholesterol and uridine levels in blood are potential nutritional biomarkers for clinical progression in Alzheimer's disease: The NUDAD project. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12120.	1.2	7
524	Psychosocial Effects of COVID-19 Measures on (Pre-)Dementia Patients During Second Lockdown. Journal of Alzheimer's Disease, 2022, 86, 931-939.	1.2	7
525	The Effect of Alzheimerâ€™s Disease-Associated Genetic Variants on Longevity. Frontiers in Genetics, 2021, 12, 748781.	1.1	7
526	Volumetric MRI predicts rate of cognitive decline related to AD and cerebrovascular disease. Neurology, 2003, 60, 1558-1559.	1.5	6
527	The effect of APOE genotype on clinical phenotype in Alzheimer disease. Neurology, 2007, 68, 624-624.	1.5	6
528	Knowing the natural course of biomarkers in AD: Longitudinal MRI, CSF and PET data. Journal of Nutrition, Health and Aging, 2009, 13, 353-355.	1.5	6
529	Neurological Signs in Relation to White Matter Hyperintensity Volumes in Memory Clinic Patients. Dementia and Geriatric Cognitive Disorders, 2010, 29, 301-308.	0.7	6
530	A novel CCM2 variant in a family with nonâ€progressive cognitive complaints and cerebral microbleeds. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2017, 174, 220-226.	1.1	6
531	Comorbid amyloidâ€Î²2 pathology affects clinical and imaging features in VCD. Alzheimer's and Dementia, 2020, 16, 354-364.	0.4	6
532	Biomarker testing in MCI patientsâ€”deciding who to test. Alzheimer's Research and Therapy, 2021, 13, 14.	3.0	6
533	Assessing the Views of Professionals, Patients, and Care Partners Concerning the Use of Computer Tools in Memory Clinics: International Survey Study. JMIR Formative Research, 2021, 5, e31053.	0.7	6
534	Genome-wide association study of frontotemporal dementia identifies a C9ORF72 haplotype with a median of 12-G4C2 repeats that predisposes to pathological repeat expansions. Translational Psychiatry, 2021, 11, 451.	2.4	6
535	BDNF-Met polymorphism and amyloid-beta in relation to cognitive decline in cognitively normal elderly: the SCIENCe project. Neurobiology of Aging, 2021, 108, 146-154.	1.5	6
536	Short Digital Spatial Memory Test Detects Impairment in Alzheimerâ€™s Disease and Mild Cognitive Impairment. Brain Sciences, 2021, 11, 1350.	1.1	6
537	Pre-Diagnostic Symptoms of Young-Onset Dementia in the General Practice up to Five Years Before Diagnosis. Journal of Alzheimer's Disease, 2022, 88, 229-239.	1.2	6
538	Stability of Progranulin Under Pre-Analytical Conditions in Serum and Cerebrospinal Fluid. Journal of Alzheimer's Disease, 2016, 53, 107-116.	1.2	5
539	P4-179: MEG Cross-Frequency Analysis in Patients With Alzheimerâ€™s Disease. , 2016, 12, P1087-P1088.		5
540	Exploring effects of Souvenaid on cerebral glucose metabolism in Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 492-500.	1.8	5

#	Article	IF	Citations
541	High occurrence of transportation and logistics occupations among vascular dementia patients: an observational study. Alzheimer's Research and Therapy, 2019, 11, 112.	3.0	5
542	Hippocampal [18F]flortaucipir BPND corrected for possible spill-in of the choroid plexus retains strong clinico-pathological relationships. NeuroImage: Clinical, 2020, 25, 102113.	1.4	5
543	Prediction of poor clinical outcome in vascular cognitive impairment: TRACEâ€VCI study. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12077.	1.2	5
544	Grey zone amyloid burden affects memory function: the SCIENCe project. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 747-756.	3.3	5
545	Challenges at the APOE locus: a robust quality control approach for accurate APOE genotyping. Alzheimer's Research and Therapy, 2022, 14, 22.	3.0	5
546	Subjective cognitive decline and selfâ€reported sleep problems: The SCIENCe project. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2022, 14, .	1.2	5
547	Design of the NLâ€ENIGMA study: Exploring the effect of Souvenaid on cerebral glucose metabolism in early Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2016, 2, 233-240.	1.8	4
548	[O2â€“12â€“03]: DURATION OF ALZHEIMER's DISEASE IN THE PRECLINICAL, PRODROMAL AND DEMENTIA STAGE: A MULTIâ€STATE MODEL ANALYSIS. Alzheimer's and Dementia, 2017, 13, P585.	0.4	4
549	How Do Different Forms of Vascular Brain Injury Relate to Cognition in a Memory Clinic Population: The TRACE-VCI Study. Journal of Alzheimer's Disease, 2019, 68, 1273-1286.	1.2	4
550	Everyday Functioning in a Community-Based Volunteer Population: Differences Between Participant- and Study Partner-Report. Frontiers in Aging Neuroscience, 2021, 13, 761932.	1.7	4
551	Grey matter network markers identify individuals with prodromal Alzheimerâ€™s disease who will show rapid clinical decline. Brain Communications, 2022, 4, fcac026.	1.5	4
552	Cerebrovascular disease in suspected nonâ€Alzheimer's pathophysiology and cognitive decline over time. European Journal of Neurology, 2022, 29, 1922-1929.	1.7	4
553	Can lumbar puncture help to identify patients with incipient Alzheimer's disease?. Nature Clinical Practice Neurology, 2006, 2, 530-531.	2.7	3
554	Prevalence and severity of microbleeds in a memory clinic setting. Neurology, 2007, 68, 391-391.	1.5	3
555	IC-P-013: DIAGNOSTIC VALUE OF AMYLOID IMAGING IN EARLY ONSET DEMENTIA. , 2014, 10, P14-P14.		3
556	P4â€224: Alzheimerâ€™s Disease Patients With Osas History Have Higher CSF Tau Levels. Alzheimer's and Dementia, 2016, 12, P1115.	0.4	3
557	[P2â€“052]: THE DUTCH BRAIN HEALTH REGISTRY: OPTIMIZING RECRUITMENT FOR DEMENTIA RESEARCH. Alzheimer's and Dementia, 2017, 13, P624.	0.4	3
558	Reply to â€œUsefulness of Plasma Amyloid as Prescreener of the Earliest Alzheimer Pathological Changes Depends on the Study Populationâ€. Annals of Neurology, 2020, 87, 155-155.	2.8	3

#	Article	IF	Citations
559	Using cerebrospinal fluid amyloidâ€beta (1â€42) in the memory clinic: Concordance with PET and use of biomarker ratios across immunoassays. Alzheimer's and Dementia, 2020, 16, e045128.	0.4	3
560	The Cognitive Online Selfâ€Test Amsterdam (COSTâ€A): Establishing norm scores in a communityâ€dwelling population. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12234.	1.2	3
561	Symptomatic Treatment of Vascular Cognitive Impairment (STREAM-VCI): Protocol for a Cross-Over Trial. JMIR Research Protocols, 2018, 7, e80.	0.5	3
562	A comparison of two approaches for modeling dementia progression in a changing patient context. International Journal of Geriatric Psychiatry, 2022, 37, .	1.3	3
563	Clinical applicability of quantitative atrophy measures on MRI in patients suspected of Alzheimerâ€™s disease. European Radiology, 2022, 32, 7789-7799.	2.3	3
564	Hippocampal volume and cognition in geriatric depression. Biological Psychiatry, 2001, 50, 68-69.	0.7	2
565	IC-01-04: Diagnostic impact of [18 F]flutemetamol amyloid imaging in young-onset dementia. , 2015, 11, P3-P4.		2
566	F2-03-04: Genetic risk factors for posterior cortical atrophy. , 2015, 11, P168-P169.		2
567	[P1â€“243]: ALPHAâ€SYNUCLEIN SPECIES AS POTENTIAL CSF BIOMARKERS FOR DEMENTIA WITH LEWY BODIES. Alzheimer's and Dementia, 2017, 13, P338.	0.4	2
568	[P1â€“375]: DATAâ€DRIVEN DIAGNOSIS OF DEMENTIA DISORDERS: THE PREDICTND VALIDATION STUDY. Alzheimer's and Dementia, 2017, 13, P405.	0.4	2
569	ICâ€Pâ€192: DISEASEâ€STAGE SPECIFIC RELATIONSHIP BETWEEN COGNITIVE RESERVE AND CLINICAL PROGRESSION IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P158.	0.4	2
570	Tau pathology, relative cerebral flow and cognition in dementia with Lewy bodies. Alzheimer's and Dementia, 2020, 16, e041048.	0.4	2
571	Development of an ultrasensitive multiplex assay for simultaneous detection of AÎ²1â€42, AÎ²1â€40, GFAP and NFâ€L in blood. Alzheimer's and Dementia, 2020, 16, e043506.	0.4	2
572	The evolution of neuropsychiatric symptoms in atypical variants of Alzheimerâ€™s disease. Alzheimer's and Dementia, 2020, 16, e045236.	0.4	2
573	A mixedâ€methods approach to establish clinically meaningful categories of impairment in instrumental activities of daily living. Alzheimer's and Dementia, 2020, 16, e045693.	0.4	2
574	Attitudes towards genetic susceptibility testing for Alzheimerâ€™s disease dementia in cognitively normal adults: A survey study. Alzheimer's and Dementia, 2020, 16, e047393.	0.4	2
575	Non-invasive Standardised Uptake Value for Verification of the Use of Previously Validated Reference Region for [18F]Flortaucipir and [18F]Florbetapir Brain PET Studies. Molecular Imaging and Biology, 2021, 23, 550-559.	1.3	2
576	Sex and Cardiovascular Function in Relation to Vascular Brain Injury in Patients with Cognitive Complaints. Journal of Alzheimer's Disease, 2021, 84, 261-271.	1.2	2

#	Article	IF	Citations
577	Comparing a Single Clinician Versus a Multidisciplinary Consensus Conference Approach for Dementia Diagnostics. Journal of Alzheimer's Disease, 2021, 83, 741-751.	1.2	2
578	A Semi-supervised Large Margin Algorithm for White Matter Hyperintensity Segmentation. Lecture Notes in Computer Science, 2016, , 104-112.	1.0	2
579	LDL cholesterol and uridine levels in blood are potential nutritional biomarkers of AD progression: The NUDAD project. Alzheimer's and Dementia, 2020, 16, .	0.4	2
580	An Operational Definition of â€˜Abnormal Cognitionâ€™ to Optimize the Prediction of Progression to Dementia: What Are Optimal Cut-Off Points for Univariate and Multivariate Normative Comparisons?. Journal of Alzheimer's Disease, 2020, 77, 1693-1703.	1.2	2
581	Dataâ€driven evidence for three distinct patterns of amyloidâ€Î² accumulation. Alzheimer's and Dementia, 2021, 17, .	0.4	2
582	Study design of FINGERâ€NL: A multidomain lifestyle intervention in Dutch older adults to prevent cognitive decline. Alzheimer's and Dementia, 2021, 17, .	0.4	2
583	Does Loss of Integrity of the Cingulum Bundle Link Amyloid-Î² Accumulation and Neurodegeneration in Alzheimerâ€™s Disease?. Journal of Alzheimer's Disease, 2022, 89, 39-49.	1.2	2
584	F5-01-02: CSF biomarkers and APOE genotype as predictors of clinical progression in patients with subjective complaints. , 2013, 9, P824-P824.		1
585	P1-258: CORTICAL PHASE CHANGES AT 7T MRI IN SUBJECTIVE COGNITIVE IMPAIRMENT AND THEIR ASSOCIATION WITH COGNITIVE FUNCTION. , 2014, 10, P402-P402.		1
586	P1-135: DIRECTED ANTERIOR-TO-POSTERIOR COMMUNICATION IN THE BRAIN IS REVERSED IN DEMENTIA WITH LEWY BODIES AND IS RELATED TO ATTENTION DEFICITS. , 2014, 10, P349-P349.		1
587	O4-01-05: CLINICALLY DIAGNOSED PROBABLE AD CASES WITH A NEGATIVE AMYLOID PET SCAN: CLINICAL FINDINGS. , 2014, 10, P250-P250.		1
588	IC-P-076: WHITE MATTER HYPERINTENSITIES PREDICT MILD COGNITIVE IMPAIRMENT AND DEMENTIA IN PATIENTS WITH SUBJECTIVE COGNITIVE COMPLAINTS. , 2014, 10, P42-P43.		1
589	IC-P-109: RATIONALE AND DESIGN OF THE NL-ENIGMA STUDY: A DUTCH 24-WEEK RANDOMISED CONTROLLED STUDY TO EXPLORE THE EFFECT OF NUTRITIONAL INTERVENTION ON BRAIN GLUCOSE METABOLISM IN EARLY ALZHEIMER DISEASE. , 2014, 10, P61-P61.		1
590	O4-01-01: DIAGNOSTIC VALUE OF AMYLOID IMAGING IN EARLY ONSET DEMENTIA. , 2014, 10, P248-P248.		1
591	P3-096: MAGNETOENCEPHALOGRAPHY IN DEMENTIA: THE STATE OF THE ART. , 2014, 10, P663-P663.		1
592	P4-089: Lower cerebral blood flow is related to more severe cognitive impairment in patients with dementia due to Alzheimer's disease. , 2015, 11, P806-P807.		1
593	O4-11-04: Performance and complications of lumbar puncture in memory clinics: Results of the multicenter lp feasibility study. , 2015, 11, P297-P297.		1
594	F2-03-02: Early onset APOE-É›4-negative Alzheimer's disease patients show faster cognitive decline on non-memory domains. , 2015, 11, P168-P168.		1

#	Article	IF	Citations
595	O3-14-04: The relation between eeg spectral analysis and clinical progression in non-demented, amyloid-positive subjects. , 2015, 11, P255-P256.		1
596	IC-P-153: Thinner Cortical Thickness in Patients With Subjective Cognitive Decline is Related to Poor Memory Performance and Faster Decline of Executive Function. , 2016, 12, P113-P114.		1
597	P4â€153: Subjective Cognitive Decline and Progression to Dementia Due to AD and Nonâ€AD in Memory Clinic and Communityâ€Based Cohorts. Alzheimer's and Dementia, 2016, 12, P1073.	0.4	1
598	O5-07-02: Personalized Risk Estimates for Mci Patients: Taking Biomarkers Into the Clinic. , 2016, 12, P393-P393.		1
599	[P3â€“386]: COMPUTED RATING SCALES FOR COGNITIVE DISORDERS FROM MRI. Alzheimer's and Dementia, 2017, 13, P1108.	0.4	1
600	[ICâ€Pâ€005]: CONCORDANCE BETWEEN CEREBROSPINAL FLUID AMYLOIDâ€Î² AND [¹⁸F]FLORBETABEN PET IN AN UNSELECTED COHORT OF MEMORY CLINIC PATIENTS. Alzheimer's and Dementia, 2017, 13, P13.	0.4	1
601	[P4â€“525]: DATAâ€DRIVEN TAUâ€PET COVARIANCE NETWORKS ENHANCE PREDICTION OF RETROSPECTIVE COGNITIVE CHANGE IN ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P1548.	0.4	1
602	P2â€645: IMPAIRED OLFACTORY AND GUSTATORY FUNCTIONING IN PATIENTS WITH ALZHEIMER'S DISEASE AND MILD COGNITIVE IMPAIRMENT: THE NUDAD PROJECT. Alzheimer's and Dementia, 2018, 14, P990.	0.4	1
603	ICâ€Pâ€092: COGNITIVELY DEFINED SUBTYPES OF ALZHEIMER'S DISEASE ARE ASSOCIATED WITH DISTINCT PATTERNS OF ATROPHY. Alzheimer's and Dementia, 2018, 14, P76.	0.4	1
604	P4â€106: DECLINE IN GREY MATTER CONNECTIVITY OVER TIME IS RELATED TO CLINICAL PROGRESSION IN MCI DUE TO AD. Alzheimer's and Dementia, 2018, 14, P1479.	0.4	1
605	P1â€602: DUTCH ONLINE REGISTRY FOR RECRUITMENT OF PARTICIPANTS FOR DEMENTIA STUDIES: HERSENONDERZOEK.NL AND BRAIN HEALTH REGISTRY. Alzheimer's and Dementia, 2018, 14, P569.	0.4	1
606	What patients want to know, and what we actually tell them: The ABIDE project. Alzheimer's and Dementia, 2020, 16, e044754.	0.4	1
607	Serum glial fibrillary acidic protein and neurofilament light as prognostic biomarkers for clinical progression in subjective cognitive decline: The SCIENCe project. Alzheimer's and Dementia, 2020, 16, e044783.	0.4	1
608	Trajectories of decline in cognitively complex everyday activities across the Alzheimerâ€™s disease continuum. Alzheimer's and Dementia, 2020, 16, e044787.	0.4	1
609	Identifying and predicting heterogeneity in cognitive decline among individuals with prodromal Alzheimer's disease using a latent class analysis. Alzheimer's and Dementia, 2020, 16, e045829.	0.4	1
610	Prediction of amyloid PET status using the LUMIPULSE G Î²â€amyloid ratio (1â€42/1â€40). Alzheimer's and Dementia, 2020, 16, e046006.	0.4	1
611	Associations Between Nutrient Intake and Corresponding Nutritional Biomarker Levels in Blood in a Memory Clinic Cohort: The NUDAD Project. Journal of the American Medical Directors Association, 2020, 21, 1436-1438.	1.2	1
612	Differential Dementia Diagnosis on Incomplete Data with Latent Trees. Lecture Notes in Computer Science, 2016, , 44-52.	1.0	1

#	Article	IF	Citations
613	Neuropsychiatric Symptoms as Predictor of Poor Clinical Outcome in Patients With Vascular Cognitive Impairment. American Journal of Geriatric Psychiatry, 2022, , .	0.6	1
614	Atâ€home assessment of cognitive performance: Establishing norm scores for the Cognitive Online Selfâ€Test Amsterdam (COSTâ€A). Alzheimer's and Dementia, 2021, 17, .	0.4	1
615	ATN classification in dementia with Lewy bodies: Association with clinical profile, cognitive decline and survival. Alzheimer's and Dementia, 2021, 17, .	0.4	1
616	The (non)sense of diagnostic computer tools in memory clinics: An international survey assessing the views of clinicians, patients and caregivers. Alzheimer's and Dementia, 2021, 17, .	0.4	1
617	The incidence of young onset dementia: A systematic review and metaâ€analysis. Alzheimer's and Dementia, 2021, 17, .	0.4	1
618	A 24-year follow-up of body mass index and cerebral atrophy. Neurology, 2005, 64, 1990-1991.	1.5	0
619	NINDS AIREN neuroimaging criteria do not distinguish stroke patients with and without dementia. Neurology, 2005, 65, 1341-1341.	1.5	0
620	Heterogeneity of White Matter Hyperintensities in Alzheimer's Disease: Post-Mortem Quantitative MRI and Neuropathology. Neuroradiology Journal, 2009, 22, 51-63.	0.6	0
621	F1-01-01: Early-onset versus late-onset Alzheimer's disease: A role for APOE e4?. , 2011, 7, S89-S89.		0
622	Cerebral microbleeds and Alzheimer's disease. , 0, , 117-124.		0
623	Reply: Cerebral microbleeds in familial Alzheimer's disease. Brain, 2012, 135, e202-e202.	3.7	0
624	S2â€02â€01: Understanding (endo)phenotypical heterogeneity: The role of age and APOE. Alzheimer's and Dementia, 2012, 8, P228.	0.4	0
625	O4â€03â€01: Differential impact of apolipoprotein E genotype on distributions of amyloid load and glucose metabolism in Alzheimer's disease. Alzheimer's and Dementia, 2012, 8, P618.	0.4	0
626	S1-02-02: Clinical and neuropsychological features as predictors from MCI to Alzheimer's-type dementia. , 2013, 9, P122-P122.		0
627	O3-05-01: Physical activity, independent functioning and emotional well-being in early-onset dementia. , 2013, 9, P526-P526.		0
628	O1-09-01: Diagnostic impact of CSF biomarkers for Alzheimer's disease in a memory clinic setting. , 2013, 9, P144-P145.		0
629	PL-02-02: PREDICTING CLINICAL PROGRESSION IN SUBJECTIVE COGNITIVE DECLINE. , 2014, 10, P162-P163.		0
630	O3-06-02: A RE-EVALUATION OF EARLY ALZHEIMER'S DISEASE BIOMARKERS ACCOUNTING FOR INACCURACY OF THE CLINICAL DIAGNOSIS. , 2014, 10, P219-P219.		0

#	Article	IF	Citations
631	Interaction between cerebral small vessel disease and neurodegenerative changes. , 0, , 298-310.		0
632	O2-13-05: APOLIPOPROTEIN A-1 IS ASSOCIATED WITH DECLINE IN PRECLINICAL AD. , 2014, 10, P195-P196.		0
633	O5-02-02: LOBAR MICROBLEEDS PREDICT STROKE IN PATIENTS WITH ALZHEIMER'S DISEASE: THE MISTRAL STUDY. , 2014, 10, P291-P292.		0
634	O2-13-03: MILD COGNITIVE IMPAIRMENT WITH SUSPECTED NON AD PATHOLOGY (SNAP): PREDICTION OF PROGRESSION TO DEMENTIA. , 2014, 10, P194-P195.		0
635	P1-223: MORE ATROPHY OF DEEP GRAY MATTER STRUCTURES IN BEHAVIORAL VARIANT FRONTOTEMPORAL DEMENTIA COMPARED TO ALZHEIMER'S DISEASE. , 2014, 10, P385-P386.		0
636	IC-P-009: NEURODEGENERATIVE AND COGNITIVE PROFILE OF PATIENTS WITH A TYPICAL PHENOTYPE OF AD BUT WITH A NEGATIVE AMYLOID SCAN. , 2014, 10, P11-P12.		0
637	IC-P-085: COMPARING ATROPHY PATTERNS IN EARLY CLINICAL STAGES ACROSS DISTINCT PHENOTYPES OF ALZHEIMER'S DISEASE. , 2014, 10, P48-P49.		0
638	P1-015: PROTEIN KINASE ACTIVITY DECREASES WITH BRAAK STAGE IN HIPPOCAMPAL POSTMORTEM BRAIN TISSUE AS REVEALED BY USING A PEPTIDE-BASED MICROARRAY PLATFORM. , 2014, 10, P309-P309.		0
639	P1-385: RATIONALE AND DESIGN OF THE NL-ENIGMA STUDY, A DUTCH 24-WEEK RANDOMISED CONTROLLED STUDY TO EXPLORE THE EFFECT OF A NUTRITIONAL INTERVENTION ON BRAIN GLUCOSE METABOLISM IN EARLY ALZHEIMER'S DISEASE. , 2014, 10, P455-P456.		0
640	O2-07-04: COGNITIVE SUBTYPES IN DEMENTIA DUE TO ALZHEIMER'S DISEASE IDENTIFIED BY LATENT CLASS ANALYSIS. , 2014, 10, P178-P179.		0
641	IC-P-077: LOBAR MICROBLEEDS PREDICT STROKE IN PATIENTS WITH ALZHEIMER'S DISEASE: THE MISTRAL STUDY. , 2014, 10, P43-P44.		0
642	O4-01-06: NEURODEGENERATIVE AND COGNITIVE PROFILE OF PATIENTS WITH A TYPICAL PHENOTYPE OF AD BUT WITH A NEGATIVE AMYLOID SCAN. , 2014, 10, P250-P251.		0
643	O2-14-03: THE REST-ACTIVITY RHYTHM IS RELATED TO THE LEVEL OF PHYSICAL ACTIVITY IN EARLY-ONSET DEMENTIA. , 2014, 10, P197-P198.		0
644	IC-P-056: MORE ATROPHY OF DEEP GRAY MATTER STRUCTURES IN BEHAVIORAL VARIANT FRONTOTEMPORAL DEMENTIA COMPARED TO ALZHEIMER'S DISEASE. , 2014, 10, P31-P32.		0
645	P1-134: LOSS OF NETWORK INTEGRATION IS RELATED TO COGNITIVE IMPAIRMENT IN DEMENTIA WITH LEWY BODIES. , 2014, 10, P349-P349.		0
646	P1-149: CSF VILIP-1 AND YKL-40, NOVEL CANDIDATE BIOMARKERS TO DIAGNOSE, PREDICT, AND MONITOR ALZHEIMER'S DISEASE. , 2014, 10, P355-P355.		0
647	P4-273: CEREBROSPINAL FLUID NEUROGRANIN AS A PROGNOSTIC MARKER IN MILD COGNITIVE IMPAIRMENT AND ALZHEIMER'S DISEASE. , 2014, 10, P884-P884.		0
648	O1-02-04: 7T T2*-WEIGHTED MRI REVEALS CORTICAL PHASE DIFFERENCES BETWEEN EARLY- AND LATE-ONSET AD. , 2014, 10, P132-P133.		0

#	Article	IF	Citations
649	P1-174: CEREBROVASCULAR DISEASE IN LATE ONSET FRONTAL LOBE SYNDROME. , 2014, 10, P363-P363.		0
650	P1-415: STUDY PROTOCOL: THE EFFECT OF PHYSICAL EXERCISE ON CEREBRAL BLOOD FLOW AND COGNITION IN PATIENTS WITH MILD VASCULAR COGNITIVE IMPAIRMENT. , 2014, 10, P465-P466.		0
651	P3-158: Grey matter network disruptions are related to amyloid beta in cognitively healthy elderly. , 2015, 11, P689-P689.		0
652	P1-174: Diagnostic impact of [18 F]flutemetamol amyloid imaging in young onset dementia. , 2015, 11, P411-P412.		0
653	P3-072: Are relations between ApoE genotype and ad-related pathology in nondemented elderly mediated by CSF apolipoproteins?. , 2015, 11, P644-P644.		0
654	O4-05-04: A four-center study on the effect of polygenic risk score on cerebrospinal fluid markers and memory decline in mild cognitive impairment patients. , 2015, 11, P279-P279.		0
655	IC-P-124: Classification of resting-state cerebral perfusion maps from patients with Alzheimer's disease and patients with frontotemporal dementia. , 2015, 11, P85-P85.		0
656	P1-093: Dementia and rapid mortality: Who's at risk?. , 2015, 11, P374-P374.		0
657	P2-298: Altered plasma and CSF levels of nutrients that enhance neuronal phospholipid synthesis in Alzheimer's disease: A retrospective cohort study. , 2015, 11, P606-P607.		0
658	P1-180: Hypometabolism of the posterior cingulate cortex is not restricted to Alzheimer's disease. , 2015, 11, P414-P414.		0
659	IC-P-079: Lower cerebral blood flow is associated with cognitive decline in patients with Alzheimer's disease. , 2015, 11, P57-P57.		0
660	IC-04-03: Grey matter network disruptions are related to amyloid-beta in cognitively healthy elderly. , 2015, 11, P11-P11.		0
661	IC-P-062: Lower cerebral blood flow is related to more severe cognitive impairment in patients with dementia due to Alzheimer's disease. , 2015, 11, P46-P47.		0
662	O3-09-02: An eeg study into functional connectivity and hubs in Alzheimer's disease: What's going on in the posterior regions?. , 2015, 11, P237-P238.		0
663	P1-166: A prospective validation study of the predictnd tool: A diagnostic decision support tool-rationale and design of the study. , 2015, 11, P408-P408.		0
664	O2-02-06: Slow gait speed and low grip strength are related to worse attention and mental speed in patients with subjective cognitive decline and mild cognitive impairment. , 2015, 11, P177-P177.		0
665	F2-03-03: Characterization of the behavioral and dysexecutive variants of Alzheimer's disease. , 2015, 11, P168-P168.		0
666	P3-142: Alzheimer's biomarkers in daily practice (ABIDE): Study design. , 2015, 11, P679-P680.		0

#	Article	IF	Citations
667	IC-P-089: Vascular and amyloid pathologies in memory clinic patients: Synergetic or independent?. , 2015, 11, P62-P62.		0
668	P4-100: Vascular and amyloid pathologies in memory clinic patients: Synergetic or independent?. , 2015, 11, P814-P814.		0
669	O1-07-02: Alzheimer's disease core biomarkers and prediction of dementia in MCI: The effect of age at onset. , 2015, 11, P140-P142.		0
670	O3-14-02: Assessing underlying Alzheimer's disease pathology in MCI patients from the amsterdam dementia cohort by use of the predictad software tool. , 2015, 11, P254-P255.		0
671	F4-02-02: The influence of severity of total comorbidity on cognitive decline and conversion to dementia in memory clinic visitors. , 2015, 11, P260-P261.		0
672	O5-02-03: Reduced cortical thickness in patients with subjective cognitive decline is related to clinical progression. , 2015, 11, P317-P317.		0
673	O5-05-03: Neurogranin, a CSF biomarker for synaptic loss, predicts decline to dementia due to Alzheimer's disease. , 2015, 11, P326-P326.		0
674	P1-297: The Diagnostic Value of Amyloid Pet in an Unselected Cohort of Memory Clinic Patients. , 2016, 12, P534-P535.		0
675	IC-03-02: Grey Matter Connectivity is Associated with Clinical Progression in Non-Demented, Amyloid Positive Patients. , 2016, 12, P9-P10.		0
676	P2â€221: Cerebral Blood Flow Measured with Phaseâ€Contrast MRI in AD, MCI and Controls. Alzheimer's and Dementia, 2016, 12, P706.	0.4	0
677	ICâ€Pâ€196: Quantification of TAU Load Using [¹⁸F]AVâ€1451 and PET. Alzheimer's and Dementia, 2016, 12, P141.	0.4	0
678	O3â€08â€01: Grey Matter Connectivity is Associated with Time to Clinical Progression in Mild Cognitive Impairment, Independent of Amyloid Status. Alzheimer's and Dementia, 2016, 12, P303.	0.4	0
679	P1â€178: Impact of Coâ€Morbid Amyloid Pathology on Clinical Phenotype of Patients with Vascular Cognitive Disorders. Alzheimer's and Dementia, 2016, 12, P472.	0.4	0
680	IC-03-05: EEG Directed Connectivity from Posterior Brain Regions is Decreased in Dementia with Lewy Bodies: A Comparison with Alzheimerâ€™s Disease And Controls. , 2016, 12, P12-P12.		0
681	P1â€284: Grey Matter Connectivity is Associated With Clinical Progression in Nonâ€Demented, Amyloid Positive Patients. Alzheimer's and Dementia, 2016, 12, P528.	0.4	0
682	P1-327: Cross-Sectional Modeling of Regional Perfusion and Gray Matter Volume in Alzheimer's Disease. , 2016, 12, P552-P553.		0
683	ICâ€Pâ€097: A Novel Neuroimaging Approach to Capture Cognitive Reserve. Alzheimer's and Dementia, 2016, 12, P74.	0.4	0
684	ICâ€Pâ€103: Active and Passive Reserve Differentially Mitigate Cognitive Symptoms in Demented and Nonâ€Demented Stages of Alzheimerâ€™s Disease. Alzheimer's and Dementia, 2016, 12, P78.	0.4	0

#	Article	IF	Citations
685	ICâ€Pâ€106: Crossâ€Sectional Modeling of Regional Perfusion and Gray Matter Volume in Alzheimer's Disease. Alzheimer's and Dementia, 2016, 12, P80.	0.4	0
686	ICâ€Pâ€108: Cerebral Blood Flow Measured With Phaseâ€Contrast MRI in AD, MCI and Controls. Alzheimer's and Dementia, 2016, 12, P82.	0.4	0
687	P2-348: Impact of Non-Pharmacologic Interventions on Cognitive, Behavioral, and Emotional Functioning in Older Adults with Subjective Cognitive Decline: A Systematic Review of Controlled Trials. , 2016, 12, P777-P777.		0
688	P2â€282: EEGâ€Directed Connectivity from Posterior Brain Regions is Decreased in Dementia with Lewy Bodies: A Comparison with Alzheimer's Disease and Controls. Alzheimer's and Dementia, 2016, 12, P738.	0.4	0
689	ICâ€Pâ€147: Atrophy Patterns Predicting Cognitive Decline in Nonâ€Demented Subjects are Independent of Amyloid Pathology. Alzheimer's and Dementia, 2016, 12, P109.	0.4	0
690	P3â€144: Cognitive Subtypes Identified Using Nonnegative Matrix Factorisation in Four Large Alzheimer's Disease Dementia Cohorts. Alzheimer's and Dementia, 2016, 12, P873.	0.4	0
691	P4â€112: Amyloid Levels in the Normal Range are Predictive for Incident Dementia in Nonâ€Demented Elderly. Alzheimer's and Dementia, 2016, 12, P1055.	0.4	0
692	P4â€191: A Novel Neuroimaging Approach to Capture Cognitive Reserve. Alzheimer's and Dementia, 2016, 12, P1095.	0.4	0
693	P4â€215: Quantification of Tau Load Using [¹⁸F]AVâ€1451 and Pet. Alzheimer's and Dementia, 2016, 12, P1109.	0.4	0
694	P4â€240: Deciding About Diagnostic Testing for Alzheimerâ€™s Disease: Patientsâ€™ Views and Experiences. Alzheimer's and Dementia, 2016, 12, P1122.	0.4	0
695	O1-01-01: Active and Passive Reserve Differentially Mitigate Cognitive Symptoms in Demented and Non-Demented Stages of Alzheimerâ€™s Disease. , 2016, 12, P169-P170.		0
696	O1â€05â€02: Effects of Up to 14 Years of Biobank Storage of CSF Biomarkers AB42, TTAU, and PTAU. Alzheimer's and Dementia, 2016, 12, P183.	0.4	0
697	O4â€02â€04: Atrophy Patterns Predicting Cognitive Decline in Nonâ€Demented Subjects are Independent of Amyloid Pathology. Alzheimer's and Dementia, 2016, 12, P335.	0.4	0
698	O4-09-04: Towards Data-Driven Medicine in Differential Diagnostics of Neurodegenerative Diseases. , 2016, 12, P355-P355.		0
699	P1â€174: Costâ€Efficient Differential Diagnostics of Neurodegenerative Diseases Using A Stratified Approach. Alzheimer's and Dementia, 2016, 12, P469.	0.4	0
700	ICâ€Pâ€011: The Diagnostic Value of Amyloid Pet in an Unselected Cohort of Memory Clinic Patients. Alzheimer's and Dementia, 2016, 12, P19.	0.4	0
701	P1-418: Cliniciansâ€™ Views and Attitudes on Shared Decision Making in Diagnostic Testing for Alzheimerâ€™s Disease. , 2016, 12, P595-P595.		0
702	P2â€335: Prevalence of Preclinical Alzheimer's Disease in Patients with Subjective Cognitive Decline: Comparison of Three European Memory Clinic Samples. Alzheimer's and Dementia, 2016, 12, P770.	0.4	0

#	Article	IF	Citations
703	P2â€342: Thinner Cortical Thickness in Patients with Subjective Cognitive Decline is Related to Poor Memory Performance and Faster Decline of Executive Function. Alzheimer's and Dementia, 2016, 12, P774.	0.4	0
704	[ICâ€Pâ€130]: MRIâ€BASED CLASSIFICATION ACCURACY OF DEMENTIA TYPE IS DETERMINED BY MRI MODALITY. Alzheimer's and Dementia, 2017, 13, P98.	0.4	0
705	[P1â€“392]: AUTOMATED SELECTION OF MULTIMODAL MRI BIOMARKERS FOR DIAGNOSIS OF DEMENTIA. Alzheimer's and Dementia, 2017, 13, P417.	0.4	0
706	[P1â€“009]: DETECTING COGNITIVE DISORDERS USING THE MUISTIKKO WEBâ€BASED COGNITIVE TEST BATTERY: VALIDATION IN THREE COHORTS. Alzheimer's and Dementia, 2017, 13, P234.	0.4	0
707	[P2â€“473]: THE EFFECTS OF AMYLOID ON SEMANTIC COMPLEXITY IN SPONTANEOUS SPEECH IN SUBJECTIVE COGNITIVE DECLINE. Alzheimer's and Dementia, 2017, 13, P821.	0.4	0
708	[P3â€“161]: GRANULOCYTES: KEY PLAYERS IN PERIPHERAL AÎ² CLEARANCE?. Alzheimer's and Dementia, 2017, 13, P995.	0.4	0
709	[P3â€“226]: PROFILING PERIPHERAL METABOLIC DYSREGULATION IN ALZHEIMER's DISEASE: THE ADDED VALUE OF MULTIPLE SIGNATURES. Alzheimer's and Dementia, 2017, 13, P1024.	0.4	0
710	[P3â€“375]: GREY MATTER CONNECTIVITY IS ASSOCIATED WITH THE RATE OF COGNITIVE DECLINE IN MILD COGNITIVE IMPAIRMENT. Alzheimer's and Dementia, 2017, 13, P1102.	0.4	0
711	[P3â€“407]: SUBJECTIVE COGNITIVE DECLINE IS ASSOCIATED WITH ALTERED POSTERIOR CINGULATE CONNECTIVITY IN ELDERLY WITH A FAMILIAL HISTORY OF ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P1120.	0.4	0
712	[P3â€“422]: CLINICAL AND RADIOLOGICAL FINDINGS IN PATIENTS WITH PATHOLOGICALLY CONFIRMED CAA. Alzheimer's and Dementia, 2017, 13, P1127.	0.4	0
713	[P3â€“566]: IMPROVING BRAIN HEALTH THROUGH AN ONLINE LIFESTYLE PROGRAM: PREFERENCES OF INDIVIDUALS WITH SUBJECTIVE COGNITIVE DECLINE. Alzheimer's and Dementia, 2017, 13, P1195.	0.4	0
714	[P4â€“219]: [¹⁸F]AV1451 BINDING POTENTIAL IN RELATION TO AMYLOID STATUS AND COGNITION IN SUBJECTS WITH SUBJECTIVE COGNITIVE DECLINE. Alzheimer's and Dementia, 2017, 13, P1352.	0.4	0
715	[P4â€“235]: PARAMETRIC IMAGING OF TAU LOAD IN ALZHEIMER's PATIENTS AND CONTROLS USING FLORTAUCIPIR. Alzheimer's and Dementia, 2017, 13, P1364.	0.4	0
716	[ICâ€Pâ€037]: SUBJECTIVE COGNITIVE DECLINE IS ASSOCIATED WITH ALTERED POSTERIOR CINGULATE CONNECTIVITY IN ELDERLY WITH A FAMILIAL HISTORY OF ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P33.	0.4	0
717	[ICâ€Pâ€055]: EFFECT OF APOEâ€Îµ2 ON REGIONAL GRAY MATTER ATROPHY AND CLINICAL PHENOTYPE IN ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P45.	0.4	0
718	[ICâ€Pâ€085]: GREY MATTER CONNECTIVITY IS ASSOCIATED WITH THE RATE OF COGNITIVE DECLINE IN MILD COGNITIVE IMPAIRMENT. Alzheimer's and Dementia, 2017, 13, P69.	0.4	0
719	[ICâ€Pâ€095]: MICROBLEEDS ARE ASSOCIATED WITH DEPRESSIVE SYMPTOMS IN ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P74.	0.4	0
720	[ICâ€Pâ€106]: PREDICTING PROGRESSION IN PREâ€DEMENTIA STAGES OF ALZHEIMER's DISEASE WITH A NEUROIMAGING MEASURE OF COGNITIVE RESERVE. Alzheimer's and Dementia, 2017, 13, P81.	0.4	0

#	Article	IF	Citations
721	[ICâ€Pâ€110]: GREY MATTER CONNECTIVITY IS RELATED TO A STEEPER LOSS OF MEMORY AND LANGUAGE FUNCTIONING OVER TIME IN PATIENTS WITH SUBJECTIVE COGNITIVE DECLINE. Alzheimer's and Dementia, 2017, 13, P87.	0.4	0
722	[ICâ€Pâ€203]: [¹⁸F]AV1451 BINDING POTENTIAL IN RELATION TO AMYLOID STATUS AND COGNITION IN SUBJECTS WITH SUBJECTIVE COGNITIVE DECLINE. Alzheimer's and Dementia, 2017, 13, P148.	0.4	0
723	[ICâ€Pâ€206]: PARAMETRIC IMAGING OF TAU LOAD IN ALZHEIMER's PATIENTS AND CONTROLS USING FLORTAUCIPIR. Alzheimer's and Dementia, 2017, 13, P150.	0.4	0
724	[TDâ€Pâ€020]: IMPROVING BRAIN HEALTH THROUGH AN ONLINE LIFESTYLE PROGRAM: PREFERENCES OF INDIVIDUALS WITH SUBJECTIVE COGNITIVE DECLINE. Alzheimer's and Dementia, 2017, 13, P166.	0.4	0
725	[P1â€“250]: DECISION TREE ANALYSIS REVEALS TWO CUTâ€OFF LEVELS FOR AMYLOID BETA IN EARLY AD DIAGNOSIS. Alzheimer's and Dementia, 2017, 13, P342.	0.4	0
726	[P1â€“326]: DETECTING COGNITIVE DISORDERS USING MUISTIKKO WEBâ€BASED COGNITIVE TEST BATTERY: VALIDATION IN THREE COHORTS. Alzheimer's and Dementia, 2017, 13, P380.	0.4	0
727	[P1â€“440]: GREY MATTER CONNECTIVITY IS RELATED TO A STEEPER LOSS OF MEMORY AND LANGUAGE FUNCTIONING OVER TIME IN PATIENTS WITH SUBJECTIVE COGNITIVE DECLINE. Alzheimer's and Dementia, 2017, 13, P451.	0.4	0
728	[P1â€“486]: OCCURRENCE AND PROFILE OF COGNITIVE IMPAIRMENT IN PATIENTS WITH HEART FAILURE, CAROTID OCCLUSIVE DISEASE AND VASCULAR COGNITIVE IMPAIRMENT: THE HEARTâ€BRAIN CONNECTION STUDY. Alzheimer's and Dementia, 2017, 13, P475.	0.4	0
729	[P2â€“207]: CONCORDANCE BETWEEN CEREBROSPINAL FLUID AMYLOIDâ€Î²2 AND [¹⁸F]FLORBETABEN PET IN AN UNSELECTED COHORT OF MEMORY CLINIC PATIENTS. Alzheimer's and Dementia, 2017, 13, P688.	0.4	0
730	[P2â€“242]: PROTEOMICS IDENTIFICATION OF NOVEL CEREBROSPINAL FLUID BIOMARKER CANDIDATES OF DEMENTIA WITH LEWY BODIES. Alzheimer's and Dementia, 2017, 13, P704.	0.4	0
731	[P2â€“249]: CONTACTINâ€1 IN CSF DISCRIMINATES DEMENTIA WITH LEWY BODIES (DLB) FROM AD AND NONâ€DEMENTED CONTROLS. Alzheimer's and Dementia, 2017, 13, P708.	0.4	0
732	[P2â€“335]: EFFECT OF APOE Îµ2 ON REGIONAL GRAY MATTER ATROPHY AND CLINICAL PHENOTYPE IN ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P748.	0.4	0
733	[F1â€“03â€“04]: BIOMARKERâ€BASED PERSONALIZED RISK ESTIMATES FOR PATIENTS WITH SUBJECTIVE COGNITIVE DECLINE. Alzheimer's and Dementia, 2017, 13, P177.	0.4	0
734	[O1â€“01â€“02]: MICROBLEEDS ARE ASSOCIATED WITH DEPRESSIVE SYMPTOMS IN ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P182.	0.4	0
735	[O1â€“05â€“03]: CSF AMYLOID BETA 1â€“42 LEVELS OBTAINED OVER 15 YEARS SHOW A DIAGNOSISâ€DEPENDENT UPWARD DRIFT. Alzheimer's and Dementia, 2017, 13, P198.	0.4	0
736	[O1â€“05â€“04]: CLINICAL PERFORMANCE OF NEUROGRANIN AS A CEREBROSPINAL FLUID BIOMARKER FOR ALZHEIMER's DISEASE: AN ASSAY COMPARISON STUDY. Alzheimer's and Dementia, 2017, 13, P199.	0.4	0
737	[O2â€“01â€“01]: CHARACTERIZING INDIVIDUALS WITH SUBJECTIVE COGNITIVE DECLINE: THE SUBJECTIVE COGNITIVE IMPAIRMENT COHORT (SCIENCE). Alzheimer's and Dementia, 2017, 13, P547.	0.4	0
738	[O2â€“10â€“06]: PROGNOSIS OF CLINICAL PROGRESSION IN SUBJECTIVE COGNITIVE DECLINE USING A CLINICAL DECISION SUPPORT SYSTEM. Alzheimer's and Dementia, 2017, 13, P579.	0.4	0

#	Article	IF	Citations
739	[O2â€“11â€“03]: PREDICTING PROGRESSION IN PREâ€DEMENTIA STAGES OF ALZHEIMER's DISEASE WITH A NEUROIMAGING MEASURE OF COGNITIVE RESERVE. Alzheimer's and Dementia, 2017, 13, P581.	0.4	0
740	[O3â€“06â€“04]: PROMINENT NONâ€MEMORY DEFICITS IN AD ARE ASSOCIATED WITH A FASTER DISEASE PROGRESSION. Alzheimer's and Dementia, 2017, 13, P912.	0.4	0
741	[DTâ€01â€“02]: THE IMPACT OF AMYLOID PET ON DIAGNOSIS AND PATIENT MANAGEMENT IN AN UNSELECTED MEMORY CLINIC COHORT: THE ABIDE PROJECT. Alzheimer's and Dementia, 2017, 13, P1474.	0.4	0
742	[P3â€“075]: PLEIOTROPHIN, A NEW BIOMARKER FOR AD, IDENTIFIED USING A NOVEL STRATEGY IN CLINICAL PROTEOMICS. Alzheimer's and Dementia, 2017, 13, P960.	0.4	0
743	P1â€256: COMMUNICATION ON DIAGNOSTIC TESTING FOR (ALZHEIMER'S) DEMENTIA: THE ABIDEâ€CLINICAL ENCOUNTER STUDY. Alzheimer's and Dementia, 2018, 14, P378.	0.4	0
744	P3â€403: LOSS OF GREY MATTER CONNECTIVITY IN THE PRECUNEUS IS ASSOCIATED WITH FASTER ATROPHY RATES IN PRECLINICAL ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P1257.	0.4	0
745	O1â€10â€06: CONTACTINâ€1 HAS ADDED VALUE FOR DISCRIMINATION OF DEMENTIA WITH LEWY BODIES FROM ALZHEIMER'S DISEASE AND PARKINSON'S DISEASE. Alzheimer's and Dementia, 2018, 14, P245.	0.4	0
746	P1â€476: CORTICAL T1â€W/T2â€W RATIO VALUES ARE HIGHER IN ALZHEIMER'S DISEASE COMPARED TO CONTROLS. Alzheimer's and Dementia, 2018, 14, P506.	0.4	0
747	O1â€14â€04: IMPACT OF WHITE MATTER HYPERINTENSITY LOCATION ON DEPRESSIVE SYMPTOMS IN MEMORY CLINIC PATIENTS: A LESIONâ€SYMPTOM MAPPING STUDY. Alzheimer's and Dementia, 2018, 14, P259.	0.4	0
748	ICâ€Pâ€111: [¹⁸F]FLORBETAPIRâ€SPECIFIC BINDING IN RELATION TO COGNITION IN SUBJECTIVE COGNITIVE DECLINE. Alzheimer's and Dementia, 2018, 14, P95.	0.4	0
749	ICâ€Pâ€222: [18F]AV1451 PET IN RELATION TO ATROPHY ACROSS THE ALZHEIMER'S DISEASE SPECTRUM. Alzheimer's and Dementia, 2018, 14, P180.	0.4	0
750	P1â€328: CONSISTENCY OF MUISTIKKO WEBâ€BASED COGNITIVE TEST WHILE PERFORMED AT CLINIC AND AT HOME. Alzheimer's and Dementia, 2018, 14, P418.	0.4	0
751	P2â€350: DETECTING FRONTOTEMPORAL DEMENTIA USING A NOVEL MRI IMAGING BIOMARKER: THE ANTERIOR VERSUS POSTERIOR INDEX. Alzheimer's and Dementia, 2018, 14, P821.	0.4	0
752	P1â€357: MEDIAN SURVIVAL IN MEMORY CLINIC COHORT IS SHORT, EVEN IN YOUNGâ€ONSET DEMENTIA. Alzheimer's and Dementia, 2018, 14, P431.	0.4	0
753	P1â€016: METHYLPHENIDATE IMPROVES EXECUTIVE FUNCTIONING IN PATIENTS WITH VASCULAR COGNITIVE IMPAIRMENT: FIRST RESULTS OF THE STREAMâ€VCI STUDY. Alzheimer's and Dementia, 2018, 14, P270.	0.4	0
754	P1â€259: SEX DIFFERENCES IN CEREBROSPINAL FLUID BIOMARKER CONCENTRATIONS ACROSS CLINICAL STAGES OF ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P380.	0.4	0
755	O2â€06â€03: AMYLOIDâ€Î²2 LOAD IS RELATED TO WORRIES IN INDIVIDUALS WITH SUBJECTIVE COGNITIVE DECLINE. Alzheimer's and Dementia, 2018, 14, P632.	0.4	0
756	P2â€248: CONTACTINâ€2 AS A POTENTIAL BIOMARKER FOR MILD COGNITIVE IMPAIRMENT. Alzheimer's and Dementia, 2018, 14, P768.	0.4	0

#	Article	IF	Citations
757	ICâ€06â€05: LOSS OF GREY MATTER CONNECTIVITY IN THE PRECUNEUS IS ASSOCIATED WITH FASTER ATROPHY RATES IN PRECLINICAL ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P13.	0.4	0
758	P2â€228: PREâ€ANALYTICAL STABILITY OF NOVEL CEREBROSPINAL FLUID BIOMARKERS FOR DEMENTIA. Alzheimer's and Dementia, 2018, 14, P755.	0.4	0
759	P3â€134: CIRCULATING METABOLITES ARE ASSOCIATED WITH WHITE MATTER HYPERINTENSITIES. Alzheimer's and Dementia, 2018, 14, P1119.	0.4	0
760	P1â€297: METABOLIC BLOODâ€BASED BIOMARKERS RELATE TO BRAIN ATROPHY AND WHITE MATTER HYPERINTENSITIES IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P401.	0.4	0
761	P3â€438: PARAMETRIC IMAGING OF [¹⁸F]FLORBETAPIR: A TESTâ€RETEST STUDY IN HEALTHY SUBJECTS AND PATIENTS WITH ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P1281.	0.4	0
762	P3â€289: HARMONIZATION OF SCD OPERATIONALIZATION ACROSS DIFFERENT MEMORY CLINIC SETTINGS: THE EUROâ€SCD STUDY. Alzheimer's and Dementia, 2018, 14, P1191.	0.4	0
763	O2â€09â€03: DIAGNOSTIC PERFORMANCE OF ELECSYS IMMUNOASSAYS FOR CEREBROSPINAL FLUID ALZHEIMER'S DISEASE BIOMARKERS IN A NONâ€ACADEMIC MULTICENTER MEMORY CLINIC COHORT: THE ABIDE PROJECT. Alzheimer's and Dementia, 2018, 14, P641.	0.4	0
764	P2â€349: DIFFERENT COMBINATIONS OF DIAGNOSTIC TESTS DISCRIMINATE SPECIFIC SUBTYPES OF DEMENTIA. Alzheimer's and Dementia, 2018, 14, P820.	0.4	0
765	P2â€352: COMMUNICATING UNCERTAINTY WHEN DISCLOSING DIAGNOSTIC TEST RESULT: THE ABIDEâ€CLINICAL ENCOUNTER STUDY. Alzheimer's and Dementia, 2018, 14, P823.	0.4	0
766	P1â€656: NUTRITIONAL STATUS AND BODY COMPOSITION OF PATIENTS WITH AD, MCI AND SUBJECTIVE COGNITIVE DECLINE: THE NUDAD PROJECT. Alzheimer's and Dementia, 2018, 14, P593.	0.4	0
767	P2â€363: LATENT ATROPHY FACTORS IN POSTERIOR CORTICAL ATROPHY RELATE TO SPECIFIC COGNITIVE IMPAIRMENTS. Alzheimer's and Dementia, 2018, 14, P830.	0.4	0
768	P2â€134: THE ADDED VALUE OF EXTREME PHENOTYPES IN ALZHEIMER'S DISEASE CASEâ€CONTROL STUDIES. Alzheimer's and Dementia, 2018, 14, P719.	0.4	0
769	P2â€360: [¹⁸F]AV1451 PET IN RELATION TO ATROPHY ACROSS THE ALZHEIMER'S DISEASE SPECTRUM. Alzheimer's and Dementia, 2018, 14, P827.	0.4	0
770	P3â€264: UNBIASED METHOD TO DETERMINE CUTâ€POINTS FOR CSF TOTAL TAU LEVELS REVEALS PRESENCE OF BIOLOGICAL SUBTYPES IN A LARGE ALZHEIMER'S DISEASE POPULATION. Alzheimer's and Dementia, 2018, 14, P1176.	0.4	0
771	O2â€03â€03: COGNITIVELY DEFINED SUBTYPES OF ALZHEIMER'S DISEASE ARE ASSOCIATED WITH DISTINCT PATTERNS OF ATROPHY. Alzheimer's and Dementia, 2018, 14, P615.	0.4	0
772	P4â€038: IS SORL1 AN AUTOSOMAL DOMINANT ALZHEIMER GENE?. Alzheimer's and Dementia, 2018, 14, P1447.	0.4	0
773	P2â€500: PHYSICAL PERFORMANCE IN RELATION TO COGNITIVE FUNCTIONING IN PATIENTS WITH DISORDERS ALONG THE HEARTâ€BRAIN AXIS. Alzheimer's and Dementia, 2018, 14, P921.	0.4	0
774	O2â€06â€01: [¹⁸F]FLORBETAPIR SPECIFIC BINDING IN RELATION TO COGNITION IN SUBJECTIVE COGNITIVE DECLINE. Alzheimer's and Dementia, 2018, 14, P630.	0.4	0

#	Article	IF	Citations
775	O5â€04â€01: A RARE GENETIC VARIANT IN THE PLCG2 GENE IS ASSOCIATED WITH A REDUCED RISK OF ALL MAJOR TYPES OF DEMENTIA AND AN INCREASED RISK TO REACH AN EXTREMELY OLD AGE. Alzheimer's and Dementia, 2018, 14, P1648.	0.4	0
776	ICâ€Pâ€093: LATENT ATROPHY FACTORS IN POSTERIOR CORTICAL ATROPHY RELATE TO SPECIFIC COGNITIVE IMPAIRMENTS. Alzheimer's and Dementia, 2018, 14, P79.	0.4	0
777	ICâ€Pâ€033: LONGITUDINAL CHANGES IN GREY MATTER CONNECTIVITY ARE RELATED TO COGNITIVE DECLINE IN PRODROMAL ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P37.	0.4	0
778	P3â€342: INFLUENCE OF NETWORK CONSTRUCTION METHODS ON PATH LENGTH VALUES IN ALZHEIMER'S DISEASE: A MULTIâ€STUDY ANALYSIS OF MRI CONNECTIVITY STUDIES. Alzheimer's and Dementia, 2018, 14, P1214.	0.4	0
779	ICâ€Pâ€032: INFLUENCE OF NETWORK CONSTRUCTION METHODS ON PATH LENGTH VALUES IN ALZHEIMER'S DISEASE: A MULTIâ€STUDY ANALYSIS OF MRI CONNECTIVITY STUDIES. Alzheimer's and Dementia, 2018, 14, P36.	0.4	0
780	F5â€05â€04: THE USE OF RESIDUAL METHODS TO CAPTURE COGNITIVE RESERVE AND STUDY CLINICAL PROGRESSION IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P1633.	0.4	0
781	P1â€467: DISEASEâ€STAGEâ€“SPECIFIC RELATIONSHIP BETWEEN COGNITIVE RESERVE AND CLINICAL PROGRESSION IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P500.	0.4	0
782	O3â€13â€06: TAKING AMYLOID PET INTO THE CLINIC: INDIVIDUALIZED RISK PREDICTION IN MCI PATIENTS â€" THE ABIDE PROJECT. Alzheimer's and Dementia, 2018, 14, P1058.	0.4	0
783	O2â€15â€06: CSF AMYLOIDâ€Î² PEPTIDES IN DEMENTIA WITH LEWY BODIES AND ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P663.	0.4	0
784	O3â€14â€03: IDENTIFICATION OF NOVEL CEREBROSPINAL FLUID BIOMARKER CANDIDATES FOR DEMENTIA WITH LEWY BODIES: A PROTEOMIC APPROACH. Alzheimer's and Dementia, 2018, 14, P1060.	0.4	0
785	O2â€15â€04: ROBUST INDIVIDUALIZED PREDICTION MODELS WHICH ARE APPLICABLE ACROSS DIFFERENT COHORTS. Alzheimer's and Dementia, 2018, 14, P661.	0.4	0
786	O5â€01â€03: ATROPHY SUBTYPES IN ALZHEIMER'S DISEASE IDENTIFIED THROUGH NONâ€NEGATIVE MATRIX FACTORIZATION. Alzheimer's and Dementia, 2018, 14, P1638.	0.4	0
787	P2â€284: NUTRITIONAL MARKERS ASSOCIATED WITH CLINICAL PROGRESSION IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT AND SUBJECTIVE COGNITIVE DECLINE: THE NUDAD STUDY. Alzheimer's and Dementia, 2018, 14, P789.	0.4	0
788	P3â€617: NUTRITIONAL INTAKE IN SUBJECTIVE COGNITIVE DECLINE: ROOM FOR IMPROVEMENT?. Alzheimer's and Dementia, 2018, 14, P1366.	0.4	0
789	F4â€08â€01: PLASMA AMYLOID AS A PREâ€SCREENING TOOL FOR AMYLOID POSITIVITY IN SUBJECTIVE COGNITIVE DECLINE. Alzheimer's and Dementia, 2018, 14, P1394.	0.4	0
790	ICâ€Pâ€187: CORTICAL T1â€W/T2â€W RATIO VALUES ARE HIGHER IN ALZHEIMER'S DISEASE COMPARED TO CONTROLS. Alzheimer's and Dementia, 2018, 14, P156.	0.4	0
791	6071Extent of hypertensive exposure in relation to vascular brain injury and cognitive impairment using heart-brain magnetic resonance imaging; The Heart-Brain Connection Study. European Heart Journal, 2019, 40, .	1.0	0
792	ICâ€Pâ€100: A LONGITUDINAL STUDY OF THE EFFECTS OF EDUCATION AND INTRACRANIAL VOLUME ON COGNITIVE CHANGES AND MORTALITY RATES IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2019, 15, P87.	0.4	0

#	Article	IF	Citations
793	F2â€01â€01: NEURODEVELOPMENTAL DIFFERENCES AND ENVIRONMENTAL INSULTS INVERSELY CORRELATE WITH AGE OF ONSET IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2019, 15, P515.	0.4	0
794	ICâ€Pâ€025: GREY MATTER CONNECTIVITY TRAJECTORIES ACROSS THE ALZHEIMER'S DISEASE CONTINUUM AND ASSOCIATIONS WITH COGNITIVE DECLINE. Alzheimer's and Dementia, 2019, 15, P32.	0.4	0
795	ICâ€02â€01: GREY MATTER CONNECTIVITY TRAJECTORIES ACROSS THE ALZHEIMER'S DISEASE CONTINUUM AND ASSOCIATIONS WITH COGNITIVE DECLINE. Alzheimer's and Dementia, 2019, 15, P1.	0.4	0
796	ICâ€Pâ€076: FDGâ€PET REVEALS DISTINCT HYPOMETABOLIC TRAJECTORIES IN COGNITIVELYâ€DEFINED SUBGROUPS OF ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2019, 15, P68.	0.4	0
797	ICâ€Pâ€015: VOXELâ€BASED AMYLOID PET STAGING FOR THE WHOLE ALZHEIMER'S DISEASE CONTINUUM Alzheimer's and Dementia, 2019, 15, P24.	0.4	0
798	P1â€291: THE ASSOCIATION BETWEEN AFFECTIVE SYMPTOMS AND ALZHEIMER'S DISEASE BIOMARKERS ACROSS THE DISEASE SPECTRUM. Alzheimer's and Dementia, 2019, 15, P355.	0.4	0
799	Improving patient care through a national memory clinic network. Alzheimer's and Dementia, 2020, 16, e039017.	0.4	0
800	Gait disturbances are associated with increased CSF tau levels in a memory clinic cohort. Alzheimer's and Dementia, 2020, 16, e040152.	0.4	0
801	Determinants of cognitive decline and dementia in stage 2: The SCIENCe project. Alzheimer's and Dementia, 2020, 16, e040263.	0.4	0
802	Functional interpretation of genetic risk loci for dementia using a protein quantitative trait loci (pQTLs) approach in cerebrospinal fluid. Alzheimer's and Dementia, 2020, 16, e040774.	0.4	0
803	Amyloidâ€Î² deposition in cognitively normal oldestâ€old is associated with cortical thinning and faster memory decline. Alzheimer's and Dementia, 2020, 16, e040991.	0.4	0
804	Singleâ€cell profiling of circulating and brainâ€resident immune cells in a mouse model for amyloidosis and in aged mice. Alzheimer's and Dementia, 2020, 16, e041789.	0.4	0
805	Polygenic risk score for Alzheimerâ€™s disease is related to amyloid positivity in subjective cognitive decline: The SCIENCe project. Alzheimer's and Dementia, 2020, 16, e042116.	0.4	0
806	Biomarker testing in MCI patients: Deciding who to tap. Alzheimer's and Dementia, 2020, 16, e042735.	0.4	0
807	Amyloidâ€Î² deposition in cognitively normal oldestâ€old is associated with cortical thinning and faster memory decline. Alzheimer's and Dementia, 2020, 16, e042768.	0.4	0
808	Gray matter atrophy, but not vascular brain injury is related to cognitive impairment in patients with heart failure. Alzheimer's and Dementia, 2020, 16, e042892.	0.4	0
809	Dutch Brain Research Registry for online study participant recruitment: Design and first results. Alzheimer's and Dementia, 2020, 16, e044738.	0.4	0
810	An RCT to identify best practices for disclosure of amyloid imaging results in mild cognitive impairment: The ABIDE simulation study. Alzheimer's and Dementia, 2020, 16, e044761.	0.4	0

#	Article	IF	Citations
811	Amyloid pathology, but not vascular pathology, is associated with risk of incident dementia in nonâ€demented memory clinic participants. Alzheimer's and Dementia, 2020, 16, e045196.	0.4	0
812	Grey zone amyloid burden heralds future memory decline: The SCIENCe Project. Alzheimer's and Dementia, 2020, 16, e045210.	0.4	0
813	Educational video increases patientsâ€™ knowledge regarding the lumbar puncture procedure: Results of a randomized controlled trial in clinical practice. Alzheimer's and Dementia, 2020, 16, e045719.	0.4	0
814	Plasma amyloidâ€Î²2 oligomerization assay as a screening test for abnormal amyloid status. Alzheimer's and Dementia, 2020, 16, e045754.	0.4	0
815	CSF biomarkers for frontotemporal dementia and its pathological subtypes. Alzheimer's and Dementia, 2020, 16, e045851.	0.4	0
816	Associations of brain connectivity with disease progression and cognitive dysfunction in autosomalâ€dominant Alzheimer disease depend on imaging modality. Alzheimer's and Dementia, 2020, 16, e045942.	0.4	0
817	Study partnerâ€and selfâ€reported difficulties in cognitively complex everyday activities in participants without objective cognitive impairment. Alzheimer's and Dementia, 2020, 16, e046015.	0.4	0
818	A Cystatin C Cleavage ELISA Assay as a Quality Control Tool for Determining Sub-Optimal Storage Conditions of Cerebrospinal Fluid Samples in Alzheimerâ€™s Disease Research. Journal of Alzheimer's Disease, 2021, 83, 1367-1377.	1.2	0
819	Clinical Evaluation and Treatment of Cognitive Dysfunction and Dementia. , 2009, , 103-127.		0
820	Decreased integrity of the monoaminergic tract is associated with a positive response to MPH in patients with vascular cognitive impairment - proof of principle study STREAM-VCI. Cerebral Circulation - Cognition and Behavior, 2022, 3, 100128.	0.4	0
821	Clinical and analytical comparison of three assays for plasma pâ€tau isoforms on an ultrasensitive platform. Alzheimer's and Dementia, 2021, 17, .	0.4	0
822	Psychosocial effects of Corona virus measures on (preâ€)dementia patients during 2 nd lockdown. Alzheimer's and Dementia, 2021, 17, e053995.	0.4	0
823	Can we improve clinical trial design in Alzheimerâ€™s disease? The participants point of view. Alzheimer's and Dementia, 2021, 17, .	0.4	0
824	Measuring synaptic loss in early AD stages: Trajectories of SNAP25 and SYT1 using serial CSF sampling. Alzheimer's and Dementia, 2021, 17, .	0.4	0
825	A stepwise approach towards diagnostic workup in dementia using online cognitive tools. Alzheimer's and Dementia, 2021, 17, .	0.4	0
826	Mapping associations across multiple aspects of Alzheimer disease and the role of CSF biomarkers in individuals without dementia. Alzheimer's and Dementia, 2021, 17, .	0.4	0
827	Longitudinal [¹⁸ F]flortaucipir PET: Comparison of quantitative and semiâ€quantitative parameters. Alzheimer's and Dementia, 2021, 17, .	0.4	0
828	Everyday functioning in a communityâ€based volunteer population: Factors associated with concordance between participant and study partnerâ€”Report. Alzheimer's and Dementia, 2021, 17, .	0.4	0

#	Article	IF	Citations
829	Identifying and characterizing patterns of functional decline in memory clinic patients. Alzheimer's and Dementia, 2021, 17, .	0.4	0
830	Residual approaches to capture resilience and resistance in aging and Alzheimerâ€™s disease: A metaâ€analysis. Alzheimer's and Dementia, 2021, 17, .	0.4	0
831	Novel CSF inflammatory markers MIF and TREMâ€1 are increased in Alzheimerâ€™s disease. Alzheimer's and Dementia, 2021, 17, .	0.4	0
832	An accurate diagnosis contributes to delayed institutionalization and mortality: The ABIDE Project. Alzheimer's and Dementia, 2021, 17, .	0.4	0
833	Subjective cognitive decline and selfâ€reported sleep at a memory clinic: The SCIENCe project. Alzheimer's and Dementia, 2021, 17, .	0.4	0
834	Cognitive decline in possible vascular cognitive impairment (VCI): Does the form of vascular brain injury matter?. Alzheimer's and Dementia, 2021, 17, .	0.4	0
835	Predicting institutionalization and mortality across the spectrum of Alzheimerâ€™s disease. Alzheimer's and Dementia, 2021, 17, .	0.4	0
836	CSF protein panels reflecting multiple pathophysiological mechanisms for early and specific diagnosis of Alzheimerâ€™s disease. Alzheimer's and Dementia, 2021, 17, .	0.4	0
837	Youngâ€onset dementia in memory clinics in the Netherlands: PRECODEâ€GP. Alzheimer's and Dementia, 2021, 17, e053524.	0.4	0
838	Title is missing!. , 2020, 15, e0226784.		0
839	Title is missing!. , 2020, 15, e0226784.		0
840	Title is missing!. , 2020, 15, e0226784.		0
841	Title is missing!. , 2020, 15, e0226784.		0
842	Cliniciansâ€™ communication with patients receiving a MCI diagnosis: The ABIDE project. , 2020, 15, e0227282.		0
843	Cliniciansâ€™ communication with patients receiving a MCI diagnosis: The ABIDE project. , 2020, 15, e0227282.		0
844	Cliniciansâ€™ communication with patients receiving a MCI diagnosis: The ABIDE project. , 2020, 15, e0227282.		0
845	Cliniciansâ€™ communication with patients receiving a MCI diagnosis: The ABIDE project. , 2020, 15, e0227282.		0
846	The majority of the patients with a monogenic predisposition for dementia did not fulfill current criteria for genetic testing.. Alzheimer's and Dementia, 2021, 17 Suppl 3, e052075.	0.4	0